



HAL
open science

The AT1/AT2 Receptor Equilibrium Is a Cornerstone of the Regulation of the Renin Angiotensin System beyond the Cardiovascular System

Mélissa Colin, Céline Delaitre, Sébastien Foulquier, François Dupuis

► To cite this version:

Mélissa Colin, Céline Delaitre, Sébastien Foulquier, François Dupuis. The AT1/AT2 Receptor Equilibrium Is a Cornerstone of the Regulation of the Renin Angiotensin System beyond the Cardiovascular System. *Molecules*, 2023, 28 (14), pp.5481. 10.3390/molecules28145481 . hal-04183904

HAL Id: hal-04183904

<https://hal.univ-lorraine.fr/hal-04183904>

Submitted on 21 Aug 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Review

The AT₁/AT₂ Receptor Equilibrium Is a Cornerstone of the Regulation of the Renin Angiotensin System beyond the Cardiovascular System

Mélissa Colin ^{1,2}, Céline Delaitre ¹ , Sébastien Foulquier ^{2,3}  and François Dupuis ^{1,*} 

¹ CITHEFOR, Université de Lorraine, F-54000 Nancy, France; melissa.colin@univ-lorraine.fr (M.C.); celine.delaitre@univ-lorraine.fr (C.D.)

² Department of Pharmacology and Toxicology, MHeNS—School for Mental Health and Neuroscience, Maastricht University, 6200 MD Maastricht, The Netherlands; s.foulquier@maastrichtuniversity.nl

³ CARIM—School for Cardiovascular Diseases, Maastricht University, 6200 MD Maastricht, The Netherlands

* Correspondence: francois.dupuis@univ-lorraine.fr; Tel.: +33-372747274

Abstract: The AT₁ receptor has mainly been associated with the pathological effects of the renin-angiotensin system (RAS) (e.g., hypertension, heart and kidney diseases), and constitutes a major therapeutic target. In contrast, the AT₂ receptor is presented as the protective arm of this RAS, and its targeting via specific agonists is mainly used to counteract the effects of the AT₁ receptor. The discovery of a local RAS has highlighted the importance of the balance between AT₁/AT₂ receptors at the tissue level. Disruption of this balance is suggested to be detrimental. The fine tuning of this balance is not limited to the regulation of the level of expression of these two receptors. Other mechanisms still largely unexplored, such as S-nitrosation of the AT₁ receptor, homo- and heterodimerization, and the use of AT₁ receptor-biased agonists, may significantly contribute to and/or interfere with the settings of this AT₁/AT₂ equilibrium. This review will detail, through several examples (the brain, wound healing, and the cellular cycle), the importance of the functional balance between AT₁ and AT₂ receptors, and how new molecular pharmacological approaches may act on its regulation to open up new therapeutic perspectives.

Keywords: AT₁ receptor; AT₂ receptor; angiotensin II; AT₁/AT₂ balance; biased agonism; TRV120027; S-nitrosation



Citation: Colin, M.; Delaitre, C.; Foulquier, S.; Dupuis, F. The AT₁/AT₂ Receptor Equilibrium Is a Cornerstone of the Regulation of the Renin Angiotensin System beyond the Cardiovascular System. *Molecules* **2023**, *28*, 5481. <https://doi.org/10.3390/molecules28145481>

Academic Editor: Aaron T. Wright

Received: 6 June 2023

Revised: 11 July 2023

Accepted: 14 July 2023

Published: 18 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Over the past decades, the team of Professor Jeffrey Atkinson, who recently passed away (1943–2023) and who taught Pharmacology at the Faculty of Pharmacy of Nancy for over 25 years, has contributed to demonstrating the major role of the renin angiotensin system (RAS) in the regulation of the cardiovascular system and the cerebral circulation [1–4].

The RAS is an important hormonal system involved in numerous physiological processes, as shown by the copious literature devoted to the exploration and comprehension of this system since the discovery of renin in the late 19th century by Robert Tigerstedt [5]. The systemic RAS is known for its involvement in vascular homeostasis, blood pressure regulation, and sodium and water retention in the kidney [6]. Angiotensinogen, a glycoprotein produced by the liver and released in the blood is the first element of the systemic RAS. When blood pressure drops, the juxtaglomerular apparatus in the kidney releases renin, an enzyme which cleaves angiotensinogen into angiotensin I (Ang I), an inactive decapeptide. Subsequently, Ang I will be turned into angiotensin II (Ang II) by the angiotensin I-converting enzyme (ACE) [7], mainly expressed at the surface of endothelial cells. Ang II, an octapeptide, is the main endogenous ligand of the RAS, and binds to two main receptors: the angiotensin II type 1 receptor (AT₁) and the angiotensin II type 2 receptor (AT₂), both belonging to the G protein-coupled receptor (GPCR) family [8,9]. The

hydrolysis of Ang II [10] by the angiotensin II-converting enzyme 2 (ACE2) produces the heptapeptide Ang-(1-7). Ang-(1-7) mediates signaling via the Mas receptor (MasR) and the Mas-related G protein-coupled receptor member D (MrgD receptor) (Figure 1). In addition, decarboxylation of Ang-(1-7) transforms it into alamandin, which is also able to bind to the MrgD receptor. These two axes have been the subject of many recent reviews, and will not be discussed in this article [11–13]. The AT₄ receptor, whose ligand is Ang IV, has been identified as a transmembrane enzyme, insulin-regulated membrane aminopeptidase (IRAP) [14]. In addition to its vasorelaxant effect in cerebral [15] and renal [16] vascular beds, the AT₄ receptor seems to be involved in memory and in Alzheimer’s disease [17,18].




Figure 1. Overview of the different receptors and enzymes involved in the renin angiotensin system. ACE: angiotensin I-converting enzyme; ACE2: angiotensin II-converting enzyme 2; APA: aminopeptidase A; APN: aminopeptidase N; AT₁: angiotensin II type 1 receptor; AT₂: angiotensin II type 2 receptor; MLDAD: mononuclear leukocyte-derived aspartate decarboxylase; MrgD: Mas-related G protein-coupled receptor, member D.

The two main receptors for Ang II, the AT₁ and AT₂ receptors, share a similar affinity for Ang II [9] but exert opposite actions [19,20]. These characteristics suggest that the stimulation of RAS and Ang II production may lead to physiological responses that directly reflect the functional balance between AT₁ and AT₂ receptors. From a systemic point of view, most of the known effects of RAS activation (elevated blood pressure, water and sodium retention, aldosterone release...) are subsequent to AT₁ receptor activation, as the expression and activity of AT₂ receptor seem too low to counteract AT₁ receptor stimulation. Apart from the systemic RAS, many studies have shown the existence of a localized expression of RAS components in various tissues. For instance, Campbell and Habener in 1986 measured angiotensinogen mRNA levels in 17 different organs in rats; brain, spinal cord, aorta, and mesentery levels were similar to hepatic levels, whereas the levels were lower in the kidney, adrenal, atria, lung, large intestine, spleen, and stomach [21]. Moreover, in humans, the expression of angiotensinogen mRNA is also found in different organs as indicated by the Human Protein Atlas.

These results indicate that many of the tissue-specific actions of angiotensin II may be mediated by local tissue RAS, independently of the circulating RAS. Thus, at this tissue

level, a possible balance of these AT₁/AT₂ receptor appears to be of major importance in the regulation of RAS activity, and the fine tuning of this AT₁/AT₂ balance seems critical.

The objective of this review is to emphasize the importance of this local functional balance between AT₁ and AT₂ receptors in physiological and pathophysiological processes. After a brief analysis of the structure and signalization of these two receptors, which have been recently reviewed [22,23], we will highlight the importance of the AT₁/AT₂ equilibrium. We will not illustrate this point through a systematic review, but through several examples chosen to emphasize the ubiquitous aspect of this major regulation of physiological functions. As we are interested in the vascular and cerebrovascular effects of this system, these will be described first, followed by the cell cycle/cancerization process and wound healing. In the last chapters, we will discuss the mechanisms of this AT₁/AT₂ balance, as well as different perspectives to be considered in order to modulate it.

2. AT₁ and AT₂ Angiotensin II Receptors

2.1. AT₁ Receptor

The AT₁ receptor is responsible for vasoconstriction, cell growth and proliferation, oxidative stress, inflammation, and also hypertrophy and hyperplasia [24,25]. Most of these actions result from the activation of intracellular signaling pathways involving several phospholipases and kinases (see below).

This receptor is expressed in several organs such as artery walls (smooth muscle cells), wherein it is highly expressed [26], but also in the heart (cardiomyocytes) [27], kidney (glomeruli, proximal convoluted tubules) [28] and brain (neurons, microglia cells) [29]. Two isoforms, the AT_{1A} and AT_{1B} receptors [30], have been identified in rodents, showing a sequence homology of more than 96%, and identical functions. In humans, only one isoform has been identified.

The AT₁ receptor is a GPCR classically described to activate the phospholipase C (PLC) via G_q protein, although it also interacts with G_i, G_{12/13}, and G_s proteins [20].

2.1.1. Structure

Advances in protein crystallization have led to the elucidation of crystalline structures for GPCRs, providing insight into activation and signaling mechanisms. As GPCRs are often involved in diseases, these crystalline structures also pave the way for structured drug design. The emergence of X-ray crystallography allowed the first crystalline structure of the AT₁ receptor to be co-crystallized with an angiotensin II receptor blocker (ARB) [31].

AT₁ receptor is a member of the seven transmembrane or GPCR family. Its sequence of 359 amino acids includes three *N*-glycosylation sites (that enable the proper folding of the receptor and account for its trafficking to the membrane) and four cysteine residues at the extracellular regions [20] (Figure 2). In addition to the two cysteines involved in a disulfide bridge between the first and second extracellular loops as for all GPCRs, the AT₁ receptor contains an additional pair of extracellular cysteine residues. These cysteine residues are located on the N-terminal part and the third extracellular loop, and thus form a second disulfide bridge responsible for maintaining the conformation of the AT₁ receptor and its binding to Ang II [32]. The cytoplasmic region of the receptor, composed of three intracellular loops and the C-terminal tail, contains sites that can be phosphorylated by several serine/threonine kinases, such as protein kinase C (PKC), and also has four cysteine residues which are involved in disulfide bridges [20].

The AT₁ receptor can adopt three different conformations that directly influence its activity [33]. The inactive conformation is stabilized by ARBs and does not lead to any downstream signaling. The “canonical active” conformation is observed after the binding of the endogenous ligand (Ang II), and allows the activation of many different signaling pathways (see below). The binding of Ang II results in a movement of the seventh transmembrane domain on the intracellular side, allowing the recruitment of G proteins or of β-arrestin. Finally, the “active alternative” conformation (incomplete movement of the seventh transmembrane domain on the intracellular side) prevents G protein coupling to

the DRY motif of the receptor (Figure 1), and only allows recruitment and stimulation of the β -arrestin signaling pathway [33,34].




Figure 2. Snake plot of the rat AT₁A receptor (modified from [20,35,36]). Orange: amino acids for the activation of G proteins, green: amino acids for the activation of β -arrestins, purple: amino acids for the activation of G proteins and β -arrestins, blue: disulfide bridges, yellow: N-glycosylation sites. A: alanine; C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; G: glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M: methionine; N: asparagine; P: proline; Q: glutamine; R: arginine; S: serine; T: threonine; V: valine; W: tryptophane; Y: tyrosine.

2.1.2. Signaling

G Protein Pathway

As evoked above, the AT₁ receptor, once activated by Ang II, adopts the canonical active conformation, allowing its coupling to G proteins (Figure 3).

The activation of phospholipase C (PLC) is subsequent to G α_q protein activation. This activation releases the α_q and β_γ subunits of the G α_q protein. The α_q subunit activates the PLC, leading to the hydrolysis of phosphatidyl-inositol-4,5-diphosphate (PIP₂) into inositol-1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG) [37]. The production of IP₃ induces a release of calcium (Ca²⁺) from the endoplasmic reticulum, and then Ca²⁺ complexes with calmodulin; this then activates myosin light-chain kinase (MLCK). Phosphorylation of myosin light chains (MLC) leads to muscle cell contraction and thus vasoconstriction. Following the elevation in Ca²⁺ induced by the PLC, the phospholipase D (PLD) is activated, causing hydrolysis of phospholipids (mainly phosphatidylcholine) to generate phosphatidic acid, which is itself transformed into DAG [38]. Subsequently, DAG activates PKC, which induces the activation of PLC; thus, this positive feedback allows the continuous maintenance of PLC activity [39]. The G α_q subunit can also stimulate cell growth and proliferation through the activation via phosphorylation of several downstream proteins such as mitogen-activated protein kinases (MAPKs), janus kinases (JAKs), and transcription signal transducer and activator (STAT) proteins [40].

AT₁ receptor stimulation also induces the activation of phospholipase A₂ (PLA₂) via the activation of the G α_q protein. Once activated, PLA₂ allows the release of arachidonic acid from membrane phospholipids [41]. Arachidonic acid is then transformed into

eicosanoids such as prostaglandins or thromboxane [42] by cyclooxygenases or lipoxygenases. Several of these eicosanoids play a role in Ang II-induced contraction, whereas others (PGI₂, PGE₂) oppose it [42]. The AT₁ receptor may also recruit other G proteins, such as the G_{12/13} protein, involved in the activation of the RhoA/ROCK (Rho-associated protein kinase) signaling. These ROCKs are serine-threonine kinases with targets involved in the regulation of contractility [43,44].

β -Arrestins

After stimulation by Ang II, the AT₁ receptor is phosphorylated on its intracellular C-terminal serine and threonine residues by GPCR kinases (GRKs). This phosphorylation increases the affinity of β -arrestin-1 and β -arrestin-2 equally for the AT₁ receptor. The β -arrestins' recruitment is known to inhibit G protein-induced signaling by interfering with the conformation of the receptor; it is also known to initiate, with the help of clathrins and AP-2 adaptor proteins, the internalization and sequestration of the AT₁ receptor coupled to its ligand, as well as the membrane recycling of the receptors [34,45].

Originally, arrestins were identified as central players in the desensitization and internalization of GPCRs. In addition to modulating GPCR signaling, in 1999, Robert Lefkowitz's team showed that β -arrestins can also initiate a second wave of signaling [46]. Other studies, such as that of Tohgo, have shown that overexpression of β -arrestin-1 or β -arrestin-2 leads to a decrease in inositol-phosphate (IP) production following AT₁ receptor stimulation [47]. In addition to the modulation of GPCR signaling through desensitization and internalization, β -arrestins also act as signaling scaffolds for various signaling pathways.

For example, β -arrestins are able to recruit at the plasma membrane proteins belonging to the Src family (internalization of the receptor is not necessary) [48]. These Src allow the activation of different kinases such as ERKs, leading to a decrease in the production of IP following the stimulation of AT₁ receptor [47].

NADPH

Griendling et al. were the first to demonstrate the implication of nicotinamide adenine dinucleotide phosphate (NADPH) in oxidative stress mediated by the AT₁ receptor [49]. Using rat aortic VSMCs, they showed that treatment of VSMCs with Ang II for 4–6 h caused a nearly threefold increase in intracellular O₂⁻ consumption. Ang II stimulates the activity of NAD(P)H oxidase (NOX), and thus generates reactive oxygen species (ROS) [49].

NOX comprises five subunits, and in the absence of stimulation, some of its subunits are cytosolic, while others are membrane-bound [50]. Ang II, via processes involving several players such as c-Src, PLD, PKC, PI3K, and transactivation of EGFR (epidermal growth factor receptor), induces phosphorylation of the p47phox subunit, which causes the formation of a complex between cytosolic subunits, followed by transfer to the membrane, wherein the complex associates with membrane subunits to give the active form of the oxidase [50]. This will lead to the production of reactive oxygen species (ROS) such as H₂O₂ or superoxide. These ROS are able to activate transcription factors such as activator protein-1 (AP-1) and nuclear factor κ B (NF- κ B), which will induce the expression of pro-inflammatory genes [44].




Figure 3. Overview of the different signaling pathways following AT₁ receptor activation. AA: arachidonic acid; Ang II: angiotensin II; ARBs: angiotensin receptor blockers; AT₁: angiotensin II type 1 receptor; AT₂: angiotensin II type 2 receptor; Ca²⁺: calcium; DAG: diacylglycerol; ERK_{1/2}: extracellular signal regulated kinase 1/2; IP₃: inositol triphosphate; JNK: c-Jun N-terminal kinase; NFκB: nuclear factor kappa B; NOX: NADPH oxidase; PLA₂: phospholipase A₂; PLC: phospholipase C; PLD: phospholipase D; PKC: protein kinase C; ROCK: Rho-associated protein kinase; ROS: reactive oxygen species; TRV120027: β-arrestin-biased AT₁ agonists.

2.2. AT₂ Receptor

The AT₂ receptor was initially not widely studied because of its low abundance in tissues making its study more difficult. However, it seems to play an important role in the development of the circulatory system, in particular by allowing the differentiation of precursor cells into smooth muscle cells during gestation, thus influencing the structure and function of blood vessels [19]. After birth, AT₂ receptors are restricted to certain tissues such as those of the brain, heart, vascular endothelium, kidney, uterus, and ovary [20]. Besides their decrease in locomotion and exploratory behavior associated with a decrease in spontaneous movements and rearing activity, AT₂ receptor-KO mice suffer from impaired drinking response to water deprivation [51,52]. Moreover, AT₂ receptor expression is upregulated during inflammation, and its stimulation reduces organ damage [53].

2.2.1. Structure

The first crystalline structures of the AT₂ receptor were published in 2017 [54] demonstrating commonalities such as an extracellular loop 2 (ECL2) β-hairpin conformation.

The AT₂ receptor is composed of 363 amino acids and shares 34% homology with the AT₁ receptor. The AT₂ receptor has seven transmembrane domains, an extracellular amino terminus and an intracellular carboxy terminus (Figure 4) [9]. However the AT₂ receptor seems to have unique structural and functional differences, unlike other GPCRs (including AT₁ receptor), the AT₂ receptor is not internalized after stimulation by its endogenous agonist (Ang II) and this stimulation does not lead to the binding of stable GTP analogues [20].

The AT₂ receptor also has a nanomolar affinity for Ang II, similar to that of the AT₁ receptor (Table 1). At the N-terminal part AT₂ receptor has five n-glycosylation sites and 14 cysteine residues [20]. The second intracellular loop consists of a potential PKC phosphorylation site. The cytoplasmic tail contains three consensus PKC phosphorylation

sites but also a phosphorylation site for the cyclic AMP-dependent protein kinase [55]. The third intracellular loop of the receptor is involved in coupling to G_i proteins [56], and thus is responsible for inhibiting AT_1 receptor-dependent IP_3 production. This third loop is also essential for the signal transduction of AT_2 receptor via MAPK, and extracellular signal-regulated kinase (ERK) inactivation [55].




Figure 4. Snake plot of the rat AT_2 receptor (modified from [57–60]). Blue: disulfide bridges; yellow: N-glycosylation sites. Purple: Angiotensin II binding sites. A: alanine; C: cysteine; D: aspartic acid; E: glutamic acid; F: phenylalanine; G: glycine; H: histidine; I: isoleucine; K: lysine; L: leucine; M: methionine; N: asparagine; P: proline; Q: glutamine; R: arginine; S: serine; T: threonine; V: valine; W: tryptophane; Y: tyrosine.

2.2.2. Signaling

The effects produced by stimulation of the AT_2 receptor are the result of the activation of intracellular signaling pathways different from those of the AT_1 receptor [61]. It is interesting to note that unlike most other GPCRs, the AT_2 receptor does not associate with β -arrestins [62]. Although the AT_2 receptor-induced signaling pathways are not yet well understood, they involve in particular the NO, the bradykinin (BK), and the activation of several proteins with tyrosine phosphatase activity [63] (Figure 5).

G Protein Pathway

Before being cloned and identified, this receptor was considered independent of any interaction with G proteins [64]. Nevertheless, several biochemical and functional studies have indicated that the AT_2 receptor may recruit G_i [19,56], thereby resulting in activation of the NO-cyclic GMP (cGMP)-protein kinase G_i pathway [65]. Subsequently cGMP activates PKG_i , which dephosphorylates myosin light chains via MLCK, thus preventing calcium from leaving the endoplasmic reticulum.

Moreover, G_i recruitment leads to downstream activation of various phosphatases, such as MAPks, SH2-domain-containing phosphatase 1 (SHP-1), and serine/threonine phosphatase 2A (PP2A), resulting in the opening of delayed rectifier K^+ channels and inhibition of T-type Ca^{2+} channels [40]. The activation of $G_{\beta\gamma}$ subunits by the AT_2 receptor can induce the release of arachidonic acid via the PLA_2 . The metabolites produced by

arachidonic acid (prostaglandins or thromboxane) appear to contribute to AT₂ receptor-mediated vasodilation [66].

We have seen previously that AT₁ receptor-mediated vasoconstriction is mediated by the RhoA/ROCK pathway, among others,. Studies by Savoia have shown that the AT₂ receptor decreases the activation of the RhoA/ROCK pathway [67], and that this decrease seems to be associated with an increase in the expression of PKGI, which inactivates RhoA by phosphorylating it [68].

Bradykinin

Siragy et al. has suggested that AT₂ receptor activity is mediated by stimulation of bradykinin (BK) production [69]. This hypothesis was later confirmed by showing that AT₂ receptor inhibits the activity of Na⁺/H⁺ exchangers, resulting in acidification of the cell environment, which ultimately results in the release of BK [70]. AT₂ receptor-dependent stimulation of BK receptors (B₂ receptor) seems to activate protein kinase A (PKA), which phosphorylates eNOS [71]. Furthermore, the proximity of the two receptors allows heterodimerization of AT₂ receptors and B₂ receptors, increasing the production of cGMP and NO [72]. In addition to these pathways, the AT₂ receptor is capable of inducing NO-independent vasodilation. Indeed, AT₂ receptor is able to induce hyperpolarization of smooth muscle cells by inducing vasodilation mediated by potassium channels [73]. Inhibition of these channels would abolish this vasodilation.

In conclusion, via activation of the AT₂ receptor, Ang II leads to vasodilation, anti-proliferative, and pro-apoptotic effects, meaning the effects of AT₁ receptor activation can be counteracted [74].




Figure 5. Overview of the different signaling pathways following AT₂ receptor activation. AA: arachidonic acid; Ang II: angiotensin II; AT₂: angiotensin II type 2 receptor; cGMP: cyclic guanosine monophosphate; NO: nitric oxide; nNOS: neuronal nitric oxide synthase; PLA₂: phospholipase A₂; PKC: protein kinase; PP2A: serine/threonine phosphatase 2A; ROS: reactive oxygen species; SHP-1: SH2-domain-containing phosphatase 1.

3. The Functional AT₁/AT₂ Receptors Balance

We have seen previously that the RAS is expressed in several tissues. We will now discuss, through four different examples, the physiological and pathophysiological implication of the AT₁/AT₂ functional balance [75]. Several phenomena may interfere with this balance, such as a change in receptors' expression, or an increase of the production of Ang II.

3.1. Systemic Cardiovascular Impact

Most of the known physiological and pathological actions of Ang II are mediated by AT₁ receptors. One of the first systemic effects of the AT₁ receptor to be discovered was the regulation of blood pressure. A decrease in blood pressure will induce a decrease in renal perfusion, leading to a release of renin. The renin will then cleave angiotensinogen (in excess) into Ang I, which will in turn be cleaved into Ang II, which will cause vasoconstriction of the vessels, thereby increasing peripheral resistance with the effect of increasing blood pressure [76]. In addition, Ang II can also increase blood pressure via a decrease in renal excretion of water and sodium [6].

In 1999, Horiuchi and his team showed that AT₂ receptors have opposite effects to those of AT₁ receptors [19]. AT₂ receptors also play an important role in the regulation of renal function, particularly with respect to Na⁺ and water excretion, leading to a reduction in blood pressure. However, studies have shown that stimulation of the AT₂ receptors by an agonist does not always lead to a reduction in blood pressure, but that it depends on the model, as shown in this review [77].

In physiological conditions, the AT₁ receptor's effects predominate during Ang II stimulation, due to its higher abundance in tissues.

3.2. AT₁/AT₂ Balance in the Brain and Cerebral Circulation

3.2.1. Cerebral Circulation

The discovery of the presence of cerebral Ang II in 1971 revealed a cerebral RAS in dogs and rats [78]. Subsequently, AT₁ and AT₂ receptors were localized in cerebral blood vessels in rats [51], and then in the human brain [79].

In a rat cranial window model, Vincent et al. showed that Ang II-induced vasoconstriction of cerebral arterioles was abolished when an AT₁ receptor antagonist was used, resulting in vasodilation, which was itself abolished when AT₂ receptor antagonists were used [80]. In physiological conditions, the AT₁ receptor will allow vasoconstriction of cerebral arterioles while the AT₂ receptor has the opposite effect. Moreover, in the same cranial window model, our team showed that the AT₁ receptor was involved in the structural remodeling of cerebral arterioles in hypertensive rats [81]. This remodeling of cerebral arterioles induces a decrease in the internal diameter of vessels that is reversed when AT₁ receptor antagonists are used [82].

The AT₁ and AT₂ receptors and changes in the AT₁/AT₂ equilibrium are particularly important contributors to the regulation of cerebral circulation. Indeed, the vasoconstriction of cerebral arterioles observed during Ang II stimulation is the sum of AT₁ receptor-dependent vasoconstriction and AT₂ receptor-dependent vasodilation in physiological conditions.

Importantly, under pathological conditions with deregulation of the cerebral circulation, such as cerebral ischemia, altered function and expression of RAS components in the cerebral vasculature is observed. During ischemic stroke, increased AT₁ receptor-dependent vasoconstriction of cerebral vessels has been shown in the presence of Ang II, despite decreased AT₁ receptor gene expression [83]. To counteract this, it has been shown that AT₂ receptor gene expression is increased following stroke, but AT₂ receptor protein expression remains unchanged in the middle cerebral arteries, which limits the beneficial impact that AT₂ receptor agonists may have [84].

3.2.2. Cardiovascular Regulation

The two receptors are expressed inside or near the medulla oblongata, the brain region which regulates cardiac rhythm and blood pressure. They are exclusively found in the neurons rather than the glia.

The localization of AT₁ receptors in the brain has been determined primarily by receptor autoradiography [32,85,86]. These studies demonstrated a wide distribution of AT₁ receptors' expression in the brain, including several regions involved in cardiovascular regulation. This distribution of AT₁ receptors in the brain was confirmed by the development of transgenic mice expressing the AT₁ receptor fused with eGFP [87]. High densities of AT₁

receptors are found in the subfornical organ (SFO), the paraventricular nucleus (PVN), the area postrema (AP), the nucleus of the solitary tract (NTS), and the rostral ventrolateral medulla (RVLM) [87]. AT₁ receptors are almost exclusively localized in neurons rather than in microglia, or astrocytes in these cardiovascular control centers [88]. Furthermore, the AT₁ receptor appears to be predominantly expressed on glutamatergic neurons [89].

Similarly, the results obtained with AT₂ receptor-eGFP mice demonstrate the localization of AT₂ receptor-positive cells in or near brain areas that directly influence sympathetic output and blood pressure control. For example, the use of this mouse not only confirmed the presence of AT₂ receptor-containing neurons in the intermediate NTS, but also demonstrated that these neurons are predominantly GABAergic [90]. The AT₂ receptor-eGFP mouse also revealed a high concentration of AT₂ receptor-positive neurons in the AP, as well as AT₂ receptor neuronal fibers in the RVLM and PVN [90]. Furthermore, a number of AT₂ receptor-positive neuronal fibers and terminals in the PVN were found to be derived from the AT₂ receptor-containing GABAergic neurons that surround this nucleus [89].

It has been shown that AT₁ receptors can directly influence the neurons of the cardiovascular centers to induce sympatho-excitation and increase blood pressure, indeed; the mRNA expression levels of the AT₁ receptor in the RVLM and the NTS were higher in hypertensive rats in comparison to normotensive rats [91]. Furthermore, the administration of the AT₁ receptor antagonist losartan into the brain reduces blood pressure in hypertensive rats [91]. The first evidence that stimulation of the brain of AT₂ receptors lowers blood pressure was demonstrated by the fact that AT₁ receptor-mediated pressor responses to Ang II were amplified in the presence of the AT₂ receptor antagonist PD123319 [92]. Furthermore, the stimulation of RVLM AT₂ receptor by a specific agonist (CGP42112A) results in a drop in blood pressure [93].

3.2.3. Neuroinflammation

Inflammation is another example of the dysregulation of the AT₁/AT₂ receptors' balance in the brain. Cells present in the brain such as astrocytes or microglial cells are the main sources of inflammation. In general, the activation of the AT₁ receptor in macrophages leads to the activation of the pro-inflammatory axis of the RAS, while activation of the AT₂ receptor promotes the activation of an anti-inflammatory axis [94,95].

In contrast, in pathological conditions such as inflammation, these receptors (and in particular, AT₁/NOX signaling) are upregulated. NOX-derived superoxides are amplified by the activation of NF- κ B and the RhoA/ROCK pathway, leading to the production of ROS. In addition, through a feedback mechanism, activation of the RhoA/ROCK pathway enables increased expression of the AT₁ receptor via NF- κ B [96]. To compensate for this mechanism, it was shown by Rompe et al. that the AT₂ receptor can induce the dephosphorylation of I- κ B (NF- κ B inhibitor), thus allowing it to bind to NF- κ B to prevent its nuclear translocation (and transcription of the AT₁ receptor) [53].

However, it has been shown that although AT₂ receptor expression is generally upregulated, as the AT₁ receptor as a compensatory mechanism, this phenomenon attenuates during aging. For example, in young and healthy brains of rats, and as previously described, there is a balance between the pro-oxidative and pro-inflammatory axis induced by AT₁ receptor, and between the protective axis mediated by the AT₂ receptor [97]. Aging causes an overactivation of the pro-inflammatory axis of the RAS, while the protective axis is unchanged. Indeed, a significant increase in NOX activity and levels of the pro-inflammatory cytokines was observed in aged rats, which revealed a pro-oxidative and pro-inflammatory state in the aged substantia nigra [97]. Moreover, aged rats also showed upregulation of AT₁ receptor expression, which was inhibited by administration of candesartan (an AT₁ receptor blocker), and downregulation of AT₂ receptor expression [98].

Through these examples, we have seen different mechanisms of deregulation of the AT₁/AT₂ balance in the brain. Although the upregulation of the two receptors can partly explain this deregulation, it is certainly not the only element involved in the appearance of pathologies, as we will see in the following example.

3.3. Cellular Cycle

The proliferation of normal cells is regulated by kinases called cyclin-dependent kinases (CDKs). The main actors in this cell cycle are cyclins, which regulate CDKs, enabling cells to progress through the cell cycle [99]. We have seen previously that AT₁ receptors promote cell proliferation pathways, in particular via the MAPK pathway, which allows the expression of cyclin and CDKs, itself allowing the advancement of cells in the cell cycle (Figure 6) [100]. Diep et al. studied the expression of cell cycle proteins in Ang II-infused rats. A significant increase in ³H-thymidine incorporation in the mesenteric arteries was observed, reflecting the entry of cells into DNA replication phase (S phase). Furthermore, this incorporation was associated with high expression of cyclin D₁ and CDK4 [101]. The use of losartan in these animals completely abolished ³H-thymidine incorporation and restored the expression level of cyclin D₁ and CDK4.




Figure 6. AT₁ and AT₂ receptors' expression and their impact on cell cycle. AT₁ receptor: angiotensin II type 1 receptor; AT₂ receptor: angiotensin II type 2 receptor; CDK: cyclin-dependent kinases.

Conversely, AT₂ receptors are involved in the activation of anti-proliferative pathways [102]. In human aortic endothelial cells and after stimulation with C21 (an AT₂ receptor agonist), an activation of p53 protein was observed [103]. This protein is a key tumor suppressor which can lead either to a transient arrest of cell proliferation (to repair DNA damages, for example) or to an irreversible arrest of cell proliferation called senescence, leading to cell death [104]. When p53 is not activated, histone deacetylase-1 (HDAC1) deacetylates p53, resulting in its degradation; in contrast, HDAC1 inhibitors (such as the vorinostat) sensitize cells to apoptosis by increasing p53 acetylation. This AT₂ receptor-coupled HDAC1/p53 signaling pathway appears to have a role in physiological apoptosis and cell turnover involving p53 [103].

The AT₁ receptor directly induces cell hypertrophy, notably through the MAPK pathway, but also through the β -catenin pathway [105,106]. Cyclin D₁ will enable the transition from the G₀ to the G₁ phase of the cell cycle. The next expected step for cells in G₁, is the S phase, leading to cell proliferation. However, Geisterfer et al. reported that Ang II induces hypertrophy, but not proliferation, in confluent cultured rat aortic smooth muscle cells [107]. Subsequently, several studies revealed that Ang II stimulates the expression of immediate early genes exclusively expressed in the G₁ phase (c-myc and PDGF (platelet-derived growth factor)) [108]. Thus, these genes, once expressed after Ang II stimulation, will allow the return of resting cells to the G₁ phase, and not necessarily progression to S phase, which consists of G₁ phase arrest and hypertrophy [109].

In esophageal adenocarcinoma cells (EACs), Fujihara et al. showed that telmisartan induces antitumoral effects in EAC, both in vitro and in vivo. Following inhibition of

the AT₁ receptor by telmisartan, cell cycle arrest in the G₀/G₁ phase is induced via the Akt/mTOR pathway in EAC cells [110]. Similar results were obtained in breast cancer and cholangiocarcinoma cells [111]. Moreover, this stop in the cell cycle was accompanied by a high decrease in cell cycle-related proteins, such as cyclin E, cyclin D₁, and their catalytic sub-units, Cdk4 and Cdk6. These experiments show that increased cell proliferation in cancer is at least partially related to actions mediated by the AT₁ receptor. In contrast, overexpression of AT₂ receptors in SMMC7721 cells was shown to reduce S-phase cells and increase G₁-phase cells via suppression of CDK4 and cyclin D₁ expression, thereby reducing proliferation [112].

Many studies have reported that an increase in the presence of AT₁ and AT₂ receptors is found in different types of cancer, and is directly linked to a worse prognosis in terms of tumor aggressiveness [113–115]. The overexpression of the AT₁ receptor has been demonstrated in several in vitro models, such as mammary carcinoma cells in culture, pancreatic adenocarcinoma cells, and hepatocarcinoma cells, but also in vivo in various tumors including estrogen receptor positive breast cancers, glioblastoma, and ovarian cancers [116,117]. Despite its anti-proliferative effect, the AT₂ receptor has also been shown to be overexpressed by several cancers such as astrocytomas [113] and lung tumors [118] in vivo. In an astrocytoma model, it was shown that out of 133 tumors, 10% of low-grade tumors were positive for the AT₁ receptor, versus 67% for high-grade tumors; 17% of low-grade tumors were positive for the AT₂ receptor, versus 53% for high-grade tumors [113].

It has been shown in several models of cancer cells overexpressing the AT₂ receptor that this overexpression promotes apoptosis of these cells [112,119,120]. In addition, the effects of C21 were studied in prostate cancer (using human LNCaP prostate cancer cells and prostate adenocarcinoma transgenic rats) and leiomyosarcoma cells. In both studies, the authors were able to find antiproliferative and pro-apoptotic effects of the AT₂ receptor [121,122].

3.4. Wound Healing

Several studies reported dynamic changes in angiotensin receptor expression during the different phases of wound healing [123,124].

The expression of AT₁ and AT₂ receptors in the skin of young rats was first shown in 1992 by Viswanathan and Saavedra [125]. AT₁ and AT₂ receptors are expressed in human fibroblasts, keratinocytes, and vascular endothelial cells. Both AT₁ and AT₂ receptors are found in myofibroblasts and keratinocytes in rodents [126]. RAS components are present in the epidermal and dermal layers, but also in subcutaneous fat tissues, in microvessels, and in appendages such as hair follicles [126,127]. However, expression of RAS components in skin has also been demonstrated at the protein level, with results confirmed at the mRNA level [128].

Regarding the functional role of the RAS in skin physiology, a recent study by Jiang et al. reported that Ang II promotes differentiation of keratinocytes from bone marrow-derived mesenchymal stem cells (BMdSC) under physiological conditions [129]. Moreover, Ang II has been shown to increase vascular permeability to recruit inflammatory cells and to induce angiogenesis [130]; the AT₁ receptor promotes migration, while the AT₂ receptor inhibits it.

During wound healing, an organism will regulate the expression levels of AT₁ and AT₂ receptors, enabling a response to Ang II that is adapted to the situation. Immediately after wounding, an increase in both AT₁ and AT₂ receptor expression is observed, which seems slightly delayed and weaker for AT₂ receptors [131]. In cultured keratinocytes, this regulation is detectable at the mRNA level 1 h after wounding, but the protein expression of AT₁ receptor peaks at 3 h, and that of AT₂ receptor peaks at 12 h after wounding [126]. This specific early increase in AT₁ receptors could play a role in promoting blood clotting, initiating the inflammatory phase and inducing re-epithelialization by stimulating keratinocyte proliferation and migration [132,133].

In vivo, the wound healing process leads to an increase in receptor expression; this is higher for the AT₁ receptor than for the AT₂ receptor during the early phases of wound closure. Subsequently, there is a decrease in the expression of both receptors during the inflammation process, followed by an increase during re-epithelization.

Finally, during the last phase (remodeling), an increase in AT₁ and AT₂ receptors has been demonstrated, but this time with a dominance of the AT₂ receptor over the AT₁ receptor (Figure 7) [123,133].




Figure 7. AT₁ and AT₂ receptors' expression during wound healing. AT₁ receptor: angiotensin II type 1 receptor; AT₂ receptor: angiotensin II type 2 receptor.

This is consistent with what is known about both receptors, since in the early phases of wound healing and re-epithelization, a pro-proliferative action of AT₁ receptors is required to allow wound closure. Therefore, it has been shown that in mice KO for AT₁ receptors and rats treated with an AT₁ receptor antagonist, wound closure was delayed [134,135]. In contrast, in AT₂ receptor KO mice, re-epithelization was accelerated. These results support that during the wound healing process, the antiproliferative effect of AT₂ receptors is complementary to the pro-proliferative effects of AT₁ receptors under physiological conditions.

During the remodeling phase of wound healing, AT₂ receptor expression is stronger than AT₁ receptor expression. The antifibrotic properties seem essential for the formation of a resistant scar tissue. Indeed, in AT₂ receptor-KO mice, the skin breaks under lower tension than in wild-type mice [135]. This increased expression of the two receptors contributes to the localized Ang II action in the wounded area rather than in the unaffected skin. Thus, the changes in the AT₁/AT₂ receptor ratio observed in tissue repair may cause a switch in the dominating subtype, and consequently a change in the response to Ang II [136].

The formation of hypertrophic scars or keloids is a recurrent problem resulting from an insufficient control of proliferative and fibrotic processes in wound healing [137]. Indeed, it has been shown that it is the overactivated cutaneous RAS that is involved in this process via the AT₁ receptor [20,138]. Indeed, these receptors, once stimulated by Ang II, are known to act in a pro-fibrotic manner. Studies have also shown that the level of Ang II and AT₁ receptor expression were increased in hypertrophic scars and keloids in both rodents and humans. As a result, several experiments were conducted to inhibit the profibrotic effect of AT₁ receptor by using ARBs to prevent or treat hypertrophic scars and keloids in preclinical models. All these studies, regardless of the species, resulted in a reduction in scar size [139,140].

As evoked above, AT₁ and AT₂ receptors have the same affinity for Ang II, but induce opposite physiological responses. Thus, the physiological response to Ang II production will reflect the functional balance between these two receptors. In the next section, we will discuss the different mechanisms that may contribute to the fine tuning of this functional AT₁/AT₂ receptor balance.

4. Mechanisms Regulating the AT₁/AT₂ Functional Balance

4.1. Functional Opposition vs. Expression Level

The response to Ang II results from the balance between the effects of each of these receptors. As we have seen previously, the effects of the AT₁ receptor predominate because it is the most abundant.

This functional balance was confirmed *in vivo* using knockout mice for either the AT₁ receptor or AT₂ receptor. In AT_{1A} receptor KO mice, there was an absence of hypertensive response following Ang II injection, which is normally observed in wild-type mice. In addition, systemic blood pressure was markedly decreased in these mice [141]. In the same AT_{1A} receptor KO mice and after treatment with an AT₁ receptor antagonist, a decrease in blood pressure was observed in mice pretreated with ACE, thus showing that AT_{1B} receptors also seem to play a role in the regulation of blood pressure. In contrast, in AT₂ receptor KO mice, vasoconstriction to Ang II is more important than in wild-type mice [142]. Thus, in cerebral arteries, the effects observed are the sum of constrictor effects mediated by the AT₁ receptor and dilator effects mediated by the AT₂ receptor.

Furthermore, as we have seen in Section 3.4, during the wound healing phenomenon, there is a modification of the expression of the receptors according to the phase of the process: a stronger expression of the AT₁ receptor at the time of re-epithelization, and a stronger expression of the AT₂ receptor at the time of the remodeling phase.

The expression level of the receptors is also related to the mechanisms that regulate them. At the AT₁ receptor level, overexpression of ATRAP (AT₁ receptor-associated protein) inhibits AT₁ receptor-dependent PLC activation [143], inositol phosphate production, and cell proliferation [144], indicating that ATRAP acts as a negative regulator of AT₁ receptor signaling [145]. In addition, overexpression of ATRAP decreases membrane expression of the AT₁ receptor due to its increased internalization [146]. In contrast, expression of ARAP-1 (ankyrin repeat and pleckstrin homology domain-containing protein 1) restores receptor membrane expression [147]. Moreover, at the renal level, overexpression of ARAP1 in mice causes hypertension and renal hypertrophy, effects that are suppressed by an ARB, suggesting that ARAP1 potentiates AT₁ receptor signaling [148].

The AT₂ receptor interacts with ATIP (AT₂ receptor interaction protein) [149]. Decreased expression of this protein results in retention of the AT₂ receptor in cellular compartments, reducing their expression on the cell surface, and reducing AT₂ receptor-related effects. Expression of the AT₂ receptor at the membrane induces an increase in ATIP expression, creating a positive feedback loop [149]. PARP-1 (poly(ADP-ribose) polymerase-1) plays an important role in the regulation of AT₂ receptor expression. Indeed, in addition to repressing the transcription of the gene coding for the AT₂ receptor, it activates the transcription of the ATIP gene [150]. The AT₂ receptor also interacts with another protein: the transcription factor PLZF (promyelocytic zinc finger protein). Once bound to the AT₂ receptor, PLZF will cause its internalization, thus decreasing its membrane expression; then, PLZF will migrate to the nucleus, allowing the transcription of PI3K [151], which is involved in the activation of eNOS (endothelial nitric oxide synthase).

Although the level of expression may partly explain the predominance of the effects of one receptor over the other, it turns out that in some cases, this is more complex. For example, we have seen that after stroke, there is an increase in AT₁ receptor-dependent vasoconstriction, despite a decrease in AT₁ receptor gene expression [83]. Furthermore, Foulquier et al. showed that high salt intake for 4 days was associated with abolition of AT₂ receptor-mediated vasodilation because of decreased aldosterone levels, but also with decreased cerebrovascular AT₂ receptor protein levels without mRNA changes [152]. If this high salt intake is maintained for 30 days, in addition to the abolition of AT₂ receptor-mediated vasodilation, we observe AT₂ receptor-mediated vasoconstriction, although neither the mRNA nor protein levels of the AT₂ receptor are altered by high salt intake.

4.2. Direct AT₁/AT₂ Receptors Interactions

GPCRs have the ability to form homodimers and heterodimers that can change receptor properties. In this section, we will discuss the implication of these homodimers and heterodimers on AT₁ and AT₂ receptor signaling (Figure 8).

4.2.1. AT₁ Receptor Dimerization

Abdallah et al. showed that increased levels of AT₁ receptor homodimers were present on monocytes from patients with hypertension, which is an atherogenic risk factor, and that they were related to increased Ang II-dependent monocyte activity and adhesiveness [153]. This increase leads to the formation of atherosclerotic lesions. In this study, in addition to showing that inhibition of Ang II release prevents the formation of AT₁ receptor homodimers, they observed that dimerized receptors increase G_{q/11}-mediated inositol phosphate signaling [153]. In addition, the constitutive formation of homodimers of the AT₁ receptor are formed during biosynthesis, as the receptors are trafficked through the endoplasmic reticulum. Furthermore, the constitutive nature of receptor dimerization was not affected by treatment with agonists or antagonists [154]. These data show that AT₁ receptor homodimerization can enhance Ang II-mediated signaling, which may have a pathological effect (e.g., atherosclerosis), but that these homodimers are not affected by receptor agonists and antagonists.

The AT₁ receptor and B₂ receptor can form a heterodimeric complex. This heterodimerization between the AT₁ receptor and B₂ receptor in HEK-293 cells increased the efficacy and potency of Ang II, but decreased the potency and the efficacy of BK. To confirm this, the authors compared the Ang II- or BK-stimulated increase in inositol phosphates in HEK-293 cells expressing the indicated receptors. Furthermore, AT₁/B₂ heteromerization is also involved in the increase in Ang II hypersensitivity in preeclampsia [155]. Preeclampsia is a pregnancy complication characterized by high blood pressure, and it may cause serious complications for the mother and fetus [156]. The presence of AT₁/B₂ heterodimers has been reported in human placental biopsies from pregnancies with preeclampsia [157].

In 2005, Kostenis et al. showed that the AT₁ receptor could form a heterodimer with the MasR [158]. In their study, they transfected the human forms of Mas and AT₁ receptors, individually and in combination, into CHO-K1 cells, and then assessed intracellular Ca²⁺ mobilization after stimulation with different doses of Ang II. The MasR alone did not respond to Ang II stimulation, while cells expressing the AT₁ receptor increased their intracellular Ca²⁺ level. Upon coexpression of MasR with the AT₁ receptor, a reduction in the potency and maximal efficiency of Ang II in increasing Ca²⁺ mobilization was observed. In the same model, increasing concentrations of losartan induced significant rightward shifts in Ang II concentration–response curves in cells expressing both the AT₁ receptor alone and the AT₁/MasR heterodimer. In contrast, the Ang II-induced elevation of intracellular Ca²⁺ and its decrease in the presence of MasR were not affected by the presence of Ang-(1-7). Furthermore, *in vivo* data corroborate the results obtained in cell lines, as MasR-KO animals demonstrated a significant increase in the vasoactive properties of Ang II [158].

4.2.2. AT₂ Receptor Dimerization

AT₂ receptor homodimerization was first described by Miura et al. in PC12W cells and CHO cells transfected with AT₂R [159]. They also showed that these AT₂ receptor homodimers allow constitutive signaling that leads to apoptosis. Furthermore, dimerization and pro-apoptotic signaling were not altered following AT₂ receptor stimulation, suggesting that this homodimerization is ligand-independent, which has also been reported in transfected HEK-293 cells [160]. Zha et al. showed in NRK-52E rat kidney epithelial cells that AT₂ receptor homodimerization is observed under high-glucose conditions, which may be a direct effect of receptor dimerization susceptibility or an indirect effect due to increased AT₂ receptor expression under high-glucose conditions [161].

Like AT₁ receptors, AT₂ receptors can form heterodimers with B₂ receptors. We have already seen that AT₂ receptors mediate a vasodilatory cascade that includes BK, NO, and cGMP. Using a KO mouse model for B₂R, they showed that when AT₂ and B₂ receptors are simultaneously activated *in vivo*, NO and cGMP production increases [162]. In a PC12W cell model, heterodimerization of these receptors was shown without any stimulation, suggesting the presence of constitutive heterodimers [72]. Furthermore, the use of an AT₂ receptor agonist (CGP42112A) combined with a B₂ receptor agonist (BK) or antagonist (icatibant) allows for an increase in receptor expression alone, but also for the formation of heterodimers [72]. Thus, the maximal increase in cGMP and NO production is observed when AT₂ receptor is stimulated and the B₂ receptor is blocked; this result is in agreement with another study showing that B₂ receptor blockade increases the effect of AT₂ receptors on cGMP and NO production [163]. Since the rate of heterodimer formation depends on the expression level of AT₂ and B₂ receptors, controlling the expression level of these receptors would influence the formation of dimers, thus increasing (or not) the AT₂ receptors' effects.

The AT₂ receptors is also able to form a heterodimeric complex with MasR [164]. This dimerization influences the RAS-protective Ang II/AT₂ axis, resulting in increased NO production and promoting diuretic–natriuretic response in obese Zucker rats [164]. Several studies suggest that these receptors may be functionally interdependent; indeed, the AT₂ receptor antagonist (PD123319) reduced the vasodepressor effects of the MasR agonist Ang-(1-7) [165]. Similarly, Ang-(1-7) mediated endothelium-dependent vasodilation in the cerebral arteries [166] and aortic rings of salt-fed animals [167] was inhibited by PD123319 as well as the MasR antagonist (A-779). In mouse astrocytes isolated from AT₂ receptor KO, MasR was not responsive to Ang-(1-7), and in astrocytes isolated from MasR KO, AT₂ receptors were not responsive to C21, suggesting that in murine astrocytes in primary culture, AT₂ and MasR are functionally dependent on each other [168]. In contrast, another study showed that the vasoconstriction effect induced by Ang II was slightly increased, and the vasodilation induced by the AT₂ receptor agonist CGP42112A was not altered in mice KO for MasR [169].

Furthermore, using bioluminescence resonance energy transfer (BRET), the AT₂ receptor was found to form a heterodimer with the relaxin family peptide receptor 1 (RXFP1). Relaxin, by binding to RXFP1, is known to be antifibrotic by interfering with transforming growth factor β 1 (TGF- β 1). Ang II is also known to inhibit TGF- β 1 via the AT₂ receptor. Chow et al. investigated the potential interactions of relaxin with the AT₂ receptor. The antifibrotic action of relaxin in primary rat kidney myofibroblasts was reduced when combined with an AT₂ receptor antagonist (PD123319). This heterodimerization results in the activation of the NO-cGMP-dependent pathway. Although relaxin does not interact directly with the AT₂ receptor, AT₂/RXFP1 heterodimerization results in the activation of the NO-cGMP-dependent pathway, leading to the disruption of TGF- β 1 signaling and thus the latter's pro-fibrotic effect.

Last but not least, AT₂/AT₁ heterodimerization was first described by AbdAlla et al. in PC-12 cells, rat fetal fibroblasts, and human myometrial tissue samples [170]. They showed that AT₂/AT₁ dimerization was constitutive and led to inhibition of the AT₁ receptor-mediated G protein pathway. This inhibition of AT₁ receptor signaling does not require AT₂ receptor activation, as shown by the fact that AT₂/AT₁ heterodimerization is not affected by AT₂ receptor antagonists such as PD123319, and by the persistence of the effect in cells with dimers containing an AT₂ receptor mutant that is unable to bind agonists or to initiate AT₂ signaling. The authors concluded that the AT₂ receptor acts as a kind of reverse agonist of the AT₁ receptor by constitutively preventing the conformational changes necessary to initiate AT₁ receptor signaling [170].

Attenuation of AT₁ receptor signaling by the AT₂ receptor (via calcium signaling, ERK1/2 MAPK activation) as well as constitutive AT₂/AT₁ dimerization has been confirmed in studies by other groups in HeLa cells [171] or HEK-293 transfected with AT₂/AT₁ [172]. AT₂/AT₁ dimerization also appears to impact AT₂ intracellular trafficking, as AT₂/AT₁ dimers internalize upon Ang II stimulation (whereas AT₂ alone is unable to do so) [171].

More recently, a study demonstrated that AT₁ and AT₂ receptors form heterodimers that are expressed in the cells of the central nervous system (striatal neurons and microglia). These dimers are new functional units with specific signaling properties, because on the one hand, coactivation of the two receptors reduces Ang II signaling, and on the other hand, they exhibit cross-potential: i.e., candesartan (AT₁ receptor antagonist), increases the effect of AT₂ receptor agonists [172].

In a model of Parkinson's disease (6-OH-dopamine hemi-lesioned rat), the authors wanted to quantify the quantity of AT₂/AT₁ dimers in striatal sections of naive and 6-OH-dopamine hemi-lesioned rats, treated or not with L-DOPA and divided into two groups: those that are dyskinetic and those that are resistant to L-DOPA-induced dyskinesia. First, they demonstrated that the quantity of AT₂/AT₁ dimers found in the non-lesioned striatum was negligible compared to the lesioned striatum. Furthermore, dyskinetic animals on L-DOPA showed an approximately 2-fold increase in AT₂/AT₁ dimers (compared to the lesioned rat hemisphere), and dyskinesia-resistant animals showed an approximately 10-fold increase (compared to the non-lesioned control hemisphere) [172]. In this context of Parkinson's disease, the use of AT₁ receptor antagonists coupled to AT₂ receptor agonists could potentiate the neuroprotective effects via the AT₂ receptor.




Figure 8. Overview of the different dimerizations of AT₁ and AT₂ receptors and their functional impact. Ang II: angiotensin II; AT₁R: angiotensin type 1 receptor; AT₂R: angiotensin type 2 receptor; B₂R: bradykinin receptor B2; Ca²⁺: calcium; IP: inositol phosphate; MasR: Mas receptor; NO: nitric oxide; RXPF1: relaxin family peptide receptor 1.

In conclusion, the different dimerizations of AT₁ or AT₂ receptors, depending on the tissue and the co-expressed receptor (AT₁, AT₂, B₂R, MasR), cause a functional change in the activity of the receptors, modifying the AT₁/AT₂ balance without changing the expression of these receptors.

4.3. Post-Translational Modifications

Post-translational modifications are also mechanisms to modulate GPCR functions, AT₁ and AT₂ receptors being no exception.

4.3.1. N-Glycosylation

AT₁ receptor function is regulated by various post-translational modifications such as N-glycosylation [173]. To study the effects of N-glycosylation on extracellular loops (ECL), artificial N-glycosylation sequences were incorporated into ECL1, ECL2 and ECL3 [174]. In ECL1, N-glycosylation causes a very significant decrease in the ligand affinity and surface expression of the receptor; in ECL2, it leads to the synthesis of a misfolded receptor, and in ECL3 N-glycosylation produces mutant receptors with normal affinity and low surface expression. These results show that N-glycosylation sites alter many properties of the AT₁ receptor, such as targeting, folding, affinity, and surface expression [174].

Like the AT₁ receptor, the AT₂ receptor contains multiple glycosylation sites. The variability in AT₂ receptor molecular weight has been shown to be due to different degrees of N-glycosylation [175]. However, this glycosylation does not appear to be involved in AT₂ receptor binding and membrane addressing [176]. On the other hand, glycosylation of AT₂ receptor could nevertheless play a role in the stability of the receptor and its coupling with its intracellular effectors [176].

4.3.2. Phosphorylation

Phosphorylation is another post-translational modification that can occur on the AT₁ receptor [177]. Phosphorylation of AT₁ receptor serine/threonine residues is required for β -arrestin recruitment and receptor internalization [178]. In contrast, in the kidneys and arteries, GRK4 has been shown to exacerbate urinary sodium retention and vasoconstriction by increasing AT₁ receptor expression [179].

The AT₂ receptor is rapidly phosphorylated on a serine by PKC after activation by Ang II. The functional role of AT₂ receptor phosphorylation is not known. When triggered by AT₁ receptor activation, it appears to modulate the AT₂ receptor's effects, as opposed to AT₁'s effects [180].

A more recent study showed that GRK4, by increasing AT₂ receptor phosphorylation, impairs AT₂ receptor-mediated diuresis and natriuresis without decreasing mRNA or protein levels [181].

4.3.3. S-Nitrosation

S-nitrosation is a mode of post-translational modification that allows the addition of a NO group to the sulfur atom of specific cysteine residues.

The AT₁ receptor contains ten cysteine residues. Four of these cysteines are involved in disulfide bridges at the extracellular loops, one is located on the cytoplasmic tail, and the other five are distributed in the transmembrane domains of the receptor (see Section 2.1.1). The affinity of the AT₁ receptor for Ang II is decreased in the presence of sodium nitroprusside (SNP), an NO donor. An assessment of the affinity of different mutated AT₁ receptors for each of five cysteines revealed the cysteine involved in sensitivity to sodium nitroprusside, cysteine residue 289 [182].

The AT₂ receptor has 14 cysteine residues. We have seen that the four cysteines in the extracellular loops are engaged in disulfide bridges. The remaining ten cysteines are distributed on the transmembrane domains and the cytoplasmic tail.

In 2015, Jang showed that the AT₁ receptor, AT₂ receptor, and ROS appear to be involved in increasing nNOS (neuronal nitric oxide synthase) activity [183]. After stimulation with Ang II, membrane expression of the AT₁ receptor decreases, while that of the AT₂ receptor increases. In addition, losartan and L-NAME (eNOS inhibitor) inhibit translocation to the membrane of AT₂ receptor, suggesting that AT₂ receptor translocation may be NO-dependent. The SNP allows for the S-nitrosation of the AT₂ receptor, as it does for the AT₁ receptor. In addition, a mutation in cysteine 349 induces increased surface expression of the AT₂ receptor, suggesting that it plays a role in the translocation of the receptor to the membrane [183].

5. Possible Ways to Tune the AT₁/AT₂ Functional Balance

5.1. Pushing the Balance Using Agonist/Antagonist Ligands

One of the most obvious means to act on the AT₁/AT₂ functional balance is to use agonists or antagonists towards one or the other receptor.

In order to rebalance the AT₁/AT₂ balance, the use of specific molecules targeting our receptors seems to be an interesting avenue. Indeed, this would make it possible to block or activate one specific receptor, which cannot be achieved with ACE inhibitors, for example, as they prevent both receptors' activation by inhibiting Ang I cleavage.

AT₁ receptor antagonists were the first molecules discovered in this sense (Table 1). In the case of pathologies associated with AT₁ receptor, the ideal is to be able to abolish the overexpression of the receptor responsible for the imbalance in order to orient it in favor of the AT₂ receptor. AT₁ receptor antagonists are widely used to treat hypertension as well as cardiac diseases (heart failure or myocardial infarction). In vitro and in vivo, losartan is a reversible competitive AT₁ receptor antagonist that inhibits the Ang II-induced vasoconstriction of blood [184]. However, complete blockade of the receptor then amounts to promoting activation of the AT₂ receptor, which will tip the balance in the other direction instead of bringing it back to equilibrium.

Another method would be to act on the AT₂ receptor itself by using an agonist of the latter. For this, molecules capable of specifically activating the receptor have been developed, such as CGP42112A, which is a peptide, or C21, which is a synthetic compound. A study on the effects of CGP42112A in the same SHR model was performed, and the authors tested CGP42112A in the presence or absence of candesartan. The results showed that the use of candesartan alone at a high concentration lowered blood pressure in SHR rats, and that CGP42112A only provided a depressant effect in the presence of candesartan [185]. Another study on CGP42112A showed that intravenous infusion of the molecule increased NO production in pigs [186]. Wan et al. showed that the use of C21 in hypertensive rats reduced blood pressure [187]; however Foulquier et al. showed that this reduction in blood pressure was dependent on the experimental model used [77].

These studies show that the use of an AT₂ receptor agonist alone would not be sufficient to regulate the balance given the predominance of the AT₁ receptor in the pathological context. However, it would appear that combining the effects of an AT₁ receptor antagonist and an AT₂ receptor agonist would be more effective in certain pathologies such as hypertension [188,189].

We have seen that the AT₂ receptor has a rather protective role in case of pathology, but a study has shown that the use of PD123319 can reduce the inflammatory response and oxidative stress in rats with induced colitis [190]. In this same study and another one, it was demonstrated that PD123319 may have partial agonistic properties in relation to the AT₂ receptor, thus biasing the interpretation of functional data [190,191]. Another study conducted by our group showed that in an SHR model, the combination of the effects of an ARB with an ACE inhibitor induced an exacerbated decrease in middle cerebral artery contraction in SHR [192]. In this specific case, by blocking the AT₁ receptor, the AT₂ receptor will become dominant, thereby reversing the balance. This phenomenon has been described by Budzyn et al. [193].

Table 1. Angiotensin receptor ligands.

Agonists			
Compounds	AT ₁ affinity	AT ₂ affinity	References
Ang II	pIC ₅₀ = 8.1	pIC ₅₀ = 9.2	[194]
Ang III	pIC ₅₀ = 7.6	pIC ₅₀ = 9.2	[194]
Ang IV	N.A.	pIC ₅₀ = 7.3	[194]
Ang-(1-7)	pKi = 6.66	pIC ₅₀ = 6.6	[194,195]
SII	pKd = 6.5	N.A.	[196]
TRV120023	pEC ₅₀ = 7.4	N.A.	[197]
TRV120026	pEC ₅₀ = 7.6	N.A.	[197]
TRV120027	pEC ₅₀ = 7.7	Ki = 7 nM	[197]
CGP42112A	N.A.	pIC ₅₀ = 9.6	[194]
C21	N.A.	pIC ₅₀ = 8.6	[194]
Antagonists			
Compounds	AT ₁ affinity	AT ₂ affinity	References
Losartan	pIC ₅₀ = 7.4–8.7	N.A.	[198]
Candesartan	pIC ₅₀ = 9.5–9.7	N.A.	[199]
Valsartan	pIC ₅₀ = 8.6	N.A.	[200]
Telmisartan	pIC ₅₀ = 8.4	N.A.	[201]
PD123177	N.A.	pIC ₅₀ = 8.5–9.5	[202]
PD123319	N.A.	pIC ₅₀ = 8.25	[194]

N.A.: non-applicable. EC₅₀: half maximum effective concentration; IC₅₀: half maximum inhibitory concentration; Kd: dissociation constant. Ki: inhibition constant.

5.2. Selective Activation of the β -Arrestin Pathway

The use of biased agonists is another strategy to regulate the AT₁/AT₂ receptors' balance. A biased agonist is a receptor-specific ligand capable of selectively activating a single signaling pathway by preferentially stabilizing one of the receptor conformations. This phenomenon is also called "functional selectivity". In the case of the AT₁ receptor, several biased agonists have been developed that allow AT₁ receptor to adopt an alternative active conformation [45]. For example SII, TRV120027, and TRV120023 selectively activate the β -arrestin pathway while inhibiting the G protein pathway [197].

SII is a modified Ang II peptide, which can trigger the phosphorylation of the AT₁ receptor, and thus β -arrestin recruitment [203]. SII elicits GRK6 and β -arrestin 2-dependent ERK activation, and promotes β -arrestin-regulated Akt activity and mTOR phosphorylation to stimulate protein synthesis [204]. TRV120023 has been reported to only recruit β -arrestin while blocking G protein activation, enhancing myocyte contractility but without promoting hypertrophy, as seen with Ang II [205]. For example, an acute infusion of Ang II increased mean arterial pressure in male SHR, accompanied by a reduction in glomerular filtration rate, whereas TRV120023 blocked the acute infusion of an Ang II-induced hypertensive state in a dose-dependent manner [205].

TRV120027 has been studied in several preclinical studies in a heart failure model, and has shown promising results [206]. A recent study just demonstrated that β -arrestin signaling, mediated by the PAR-1 receptor, produces prolonged activation of MAPK 42/44, which increases PDGF- β secretion. It has been shown that after ischemic stroke, PDGF- β secretion can provide increased protection of endothelial function and barrier integrity [207]. Similarly, there are biased agonists that selectively activate the G protein pathway, such as TRV120055 or TRV120056 [33].

The use of biased agonists could be interesting in a pathological setting. Indeed, unlike ARBs, which completely inhibit the effects of the AT₁ receptor, β -arrestin-biased agonists will allow the activation of the β -arrestin pathway, with potentially protective effects. Activation of the β -arrestin pathway to mediate internalization could furthermore reduce the number of AT₁ receptors present at the surface. On the other hand, if AT₁ receptors are already occupied by a biased agonist, Ang II could then be able to bind to the

AT₂ receptor. These combined effects could restore the functional balance without blocking the AT₁ receptor. In addition to this internalization, β -arrestin may activate beneficial secondary signaling pathways [207].

Although TRV120027 is able to bind to the AT₂ receptor with an affinity comparable to that of the AT₁ receptor [197], no functional studies have been carried out. Furthermore, as the receptor is unable to interact with β -arrestin and be internalized, most signaling pathways function through the stimulation of the G protein pathway.

5.3. Post-Translational Regulation

We have previously shown that AT₁ and AT₂ receptors can undergo different post-translation changes (see Section 4.3).

Regarding phosphorylation, we have already established that the AT₂ receptor was not able to recruit β -arrestins as would classically be the case for GPCRs, including the AT₁ receptor. On the other hand, intervention on certain GRKs, such as GRK4, could have an effect on the AT₁/AT₂ balance because it would allow, on the one hand, the inhibition of the overexpression of AT₁ receptors at the membrane, and on the other hand, a decrease in the phosphorylation of the AT₂ receptor and thus the restoration of AT₂ receptor signaling.

Although the glycosylations of the AT₁ receptor are very important for its membrane addressing and ligand binding, for the AT₂ receptor, the role of these glycosylations remains unknown.

AT₁ and AT₂ receptors both have four cysteines involved in disulfide bridges. It has been shown that reduction of these disulfide bridges by dithiothreitol (DTT) strongly decreases Ang II binding for the AT₁ receptor, but not for the AT₂ receptor [32].

AT₁ and AT₂ receptors can undergo S-nitrosation. In a study of our group, rat middle cerebral arteries were pretreated with an NO donor, S-nitrosoglutathione (GSNO), and this led to abolition of Ang II-induced vasoconstriction [208]. The following results were found in an ex vivo rat aortic ring model. A decrease in Ang II-induced vascular contraction was observed when arteries were pretreated with GSNO. In vivo, a decrease in blood pressure response to Ang II was also detected after oral administration of GSNO [209]. In vitro experiments showed that pretreatment of HEK293 cells with GSNO seems not to alter the internalization of activated AT₁ receptors [208]. Similar to biased agonists, S-nitrosation disrupts AT₁ receptor G protein signaling, the advantage here being that NO is an endogenous product.

This post-translational modification seems to be an interesting tool for directing a rather protective response by not altering the AT₁/AT₂ balance as antagonists and/or agonists can. Indeed, we have seen that NO is one of the main second messengers of AT₂ receptors. We can envisage that the NO produced by the AT₂ receptor, which is even more important when the AT₂ receptor and B₂ receptor form a dimer, could S-nitrosate the AT₁ receptor.

In general, the use of biased agonists of the β -arrestin pathway and S-nitrosation of the AT₁ receptor allow for the interruption of the G-protein pathway. In addition, biased agonists allow the activation of signaling pathways with protective effects similar to those of the AT₂ receptor.

6. Conclusions

In summary, we have seen through several examples that the AT₁/AT₂ balance is very important from a physiological point of view, and that the disturbance of this balance leads to the appearance of pathologies, most often as a result of the dominance of the AT₁ receptor over the AT₂ receptor. However, emerging studies have shown that secondary signaling of β -arrestins could have beneficial effects. This is why a finer regulation of this balance via S-nitrosation of the receptors or the use of biased agonists seems to be interesting, and could open new therapeutic perspectives.

Author Contributions: Conceptualization, F.D., M.C. and C.D.; writing—original draft preparation, M.C.; writing—review and editing, F.D., S.F. and C.D.; supervision, F.D. and S.F.; project administration, F.D. and S.F. All authors have read and agreed to the published version of the manuscript.

Funding: This work was funded by the French Ministry of Education, Research and Technology (Paris, France, EA3452).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Abbreviations

ACE	Angiotensin-converting enzyme
Ang II	angiotensin II
ARB	AT ₁ receptor blocker
AT ₁	angiotensin II type 1 receptor
AT ₂	angiotensin II type 2 receptor
B2	bradykinin receptor
BK	bradykinin
C21	compound 21
GPCR	G protein-coupled receptor
GRKs	G protein-coupled receptor kinases
KO	knock-out
MAPK	mitogen-activated protein kinases
MasR	Mas receptor
NF-κβ	nuclear factor κβ
PKC	protein kinase C
PLA2	phospholipase A ₂
PLC	phospholipase C
RAS	renin-angiotensin system
ROS	reactive oxygen species
VSMC	vascular smooth muscle cells

References

1. Henrion, D.; Chillon, J.-M.; Capdeville-Atkinson, C.; Vinceneux-Feugier, M.; Atkinson, J. Chronic treatment with the angiotensin I converting enzyme inhibitor, perindopril, protects in vitro carbachol-induced vasorelaxation in a rat model of vascular calcium overload. *Br. J. Pharmacol.* **1991**, *104*, 966–972. [[CrossRef](#)]
2. Lartaud, I.; Bray-des-Boscs, L.; Chillon, J.M.; Atkinson, J.; Capdeville-Atkinson, C. In vivo cerebrovascular reactivity in Wistar and Fischer 344 rat strains during aging. *Am. J. Physiol. Heart Circ. Physiol.* **1993**, *264*, H851–H858. [[CrossRef](#)]
3. Régrigny, O.; Atkinson, J.; Capdeville-Atkinson, C.; Limiñana, P.; Chillon, J.-M. Effect of Lovastatin on Cerebral Circulation in Spontaneously Hypertensive Rats. *Hypertension* **2000**, *35*, 1105–1110. [[CrossRef](#)]
4. Atkinson, J. Stroke, high blood pressure and the renin–angiotensin–aldosterone system—New developments. *Front. Pharm.* **2011**, *2*, 22. [[CrossRef](#)]
5. Tigerstedt, R.; Bergman, P.Q. Niere und Kreislauf¹. *Skand. Arch. Für Physiol.* **1898**, *8*, 223–271. [[CrossRef](#)]
6. Guyton, A.C. Blood Pressure Control—Special Role of the Kidneys and Body Fluids. *Science* **1991**, *252*, 1813–1816. [[CrossRef](#)] [[PubMed](#)]
7. Skeggs, L.T.; Lentz, K.E.; Gould, A.B.; Hochstrasser, H.; Kahn, J.R. Biochemistry and kinetics of the renin-angiotensin system. *Fed. Proc.* **1967**, *26*, 42–47.
8. Murphy, T.J.; Alexander, R.W.; Griendling, K.K.; Runge, M.S.; Bernstein, K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. *Nature* **1991**, *351*, 233–236. [[CrossRef](#)] [[PubMed](#)]
9. Mukoyama, M.; Nakajima, M.; Horiuchi, M.; Sasamura, H.; Pratt, R.E.; Dzau, V.J. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. *J. Biol. Chem.* **1993**, *268*, 24539–24542. [[CrossRef](#)]

10. Sevá Pessôa, B.; van der Lubbe, N.; Verdonk, K.; Roks, A.J.M.; Hoorn, E.J.; Danser, A.H.J. Key developments in renin–angiotensin–aldosterone system inhibition. *Nat. Rev. Nephrol.* **2013**, *9*, 26–36. [[CrossRef](#)]
11. Simões e Silva, A.; Silveira, K.; Ferreira, A.; Teixeira, M. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis: Angiotensin-(1-7) in inflammation and fibrosis. *Br. J. Pharmacol.* **2013**, *169*, 477–492. [[CrossRef](#)] [[PubMed](#)]
12. Povlsen, A.; Grimm, D.; Wehland, M.; Infanger, M.; Krüger, M. The Vasoactive Mas Receptor in Essential Hypertension. *JCM* **2020**, *9*, 267. [[CrossRef](#)]
13. Schleifenbaum, J. Alamandine and Its Receptor MrgD Pair Up to Join the Protective Arm of the Renin-Angiotensin System. *Front. Med.* **2019**, *6*, 107. [[CrossRef](#)] [[PubMed](#)]
14. Chai, S.Y.; Fernando, R.; Peck, G.; Ye, S.-Y.; Mendelsohn, F.A.O.; Jenkins, T.A.; Albiston, A.L. What’s new in the renin-angiotensin system?: The angiotensin IV/AT4 receptor. *CMLS Cell. Mol. Life Sci.* **2004**, *61*, 2728–2737. [[CrossRef](#)]
15. Kramár, E.A.; Krishnan, R.; Harding, J.W.; Wright, J.W. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. *Regul. Pept.* **1998**, *74*, 185–192. [[CrossRef](#)] [[PubMed](#)]
16. Hamilton, T.A.; Handa, R.K.; Harding, J.W.; Wright, J.W. A role for the angiotensin IV/AT4 system in mediating natriuresis in the rat. *Peptides* **2001**, *22*, 935–944. [[CrossRef](#)]
17. Wilson, W.L.; Munn, C.; Ross, R.C.; Harding, J.W.; Wright, J.W. The role of the AT4 and cholinergic systems in the Nucleus Basalis Magnocellularis (NBM): Effects on spatial memory. *Brain Res.* **2009**, *1272*, 25–31. [[CrossRef](#)]
18. Royea, J.; Hamel, E. Brain angiotensin II and angiotensin IV receptors as potential Alzheimer’s disease therapeutic targets. *GeroScience* **2020**, *42*, 1237–1256. [[CrossRef](#)]
19. Horiuchi, M.; Akishita, M.; Dzau, V.J. Recent Progress in Angiotensin II Type 2 Receptor Research in the Cardiovascular System. *Hypertension* **1999**, *33*, 613–621. [[CrossRef](#)]
20. Gasparo, M.D.; Catt, K.J.; Inagami, T.; Wright, J.W.; Unger, T. International Union of Pharmacology. XXIII. The Angiotensin II Receptors. *Pharmacol. Rev.* **2000**, *52*, 415–472.
21. Campbell, D.J.; Habener, J.F. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. *J. Clin. Investig.* **1986**, *78*, 31–39. [[CrossRef](#)] [[PubMed](#)]
22. Delaitre, C.; Boisbrun, M.; Lecat, S.; Dupuis, F. Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes. *Int. J. Mol. Sci.* **2021**, *22*, 6738. [[CrossRef](#)] [[PubMed](#)]
23. Steckelings, U.M.; Widdop, R.E.; Sturrock, E.D.; Lubbe, L.; Hussain, T.; Kaschina, E.; Unger, T.; Hallberg, A.; Carey, R.M.; Sumners, C. The Angiotensin AT₂ Receptor: From a Binding Site to a Novel Therapeutic Target. *Pharmacol. Rev.* **2022**, *74*, 1051–1135. [[CrossRef](#)] [[PubMed](#)]
24. Hunyady, L.; Catt, K.J. Pleiotropic AT1 Receptor Signaling Pathways Mediating Physiological and Pathogenic Actions of Angiotensin II. *Mol. Endocrinol.* **2006**, *20*, 953–970. [[CrossRef](#)] [[PubMed](#)]
25. Forrester, S.J.; Booz, G.W.; Sigmund, C.D.; Coffman, T.M.; Kawai, T.; Rizzo, V.; Scalia, R.; Eguchi, S. Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. *Physiol. Rev.* **2018**, *98*, 1627–1738. [[CrossRef](#)]
26. Pueyo, M.E.; N’Diaye, N.; Michel, J.-B. Angiotensin II-elicited signal transduction via AT1 receptors in endothelial cells. *Br. J. Pharmacol.* **1996**, *118*, 79–84. [[CrossRef](#)]
27. Busche, S.; Gallinat, S.; Bohle, R.-M.; Reinecke, A.; Seebeck, J.; Franke, F.; Fink, L.; Zhu, M.; Sumners, C.; Unger, T. Expression of Angiotensin AT1 and AT2 Receptors in Adult Rat Cardiomyocytes after Myocardial Infarction. *Am. J. Pathol.* **2000**, *157*, 605–611. [[CrossRef](#)]
28. Siragy, H.M. AT1 and AT2 receptor in the kidney: Role in health and disease. *Semin. Nephrol.* **2004**, *24*, 93–100. [[CrossRef](#)]
29. Lenkei, Z.; Palkovits, M.; Corvol, P.; Llorens-Cortès, C. Expression of Angiotensin Type-1 (AT1) and Type-2 (AT2) Receptor mRNAs in the Adult Rat Brain: A Functional Neuroanatomical Review. *Front. Neuroendocrinol.* **1997**, *18*, 383–439. [[CrossRef](#)]
30. Jöhren, O.; Saavedra, J.M. Expression of AT1A and AT1B angiotensin II receptor messenger RNA in forebrain of 2-wk-old rats. *Am. J. Physiol. Endocrinol. Metab.* **1996**, *271*, E104–E112. [[CrossRef](#)]
31. Zhang, H.; Unal, H.; Gati, C.; Han, G.W.; Liu, W.; Zatsepin, N.A.; James, D.; Wang, D.; Nelson, G.; Weierstall, U.; et al. Structure of the Angiotensin Receptor Revealed by Serial Femtosecond Crystallography. *Cell* **2015**, *161*, 833–844. [[CrossRef](#)]
32. Ohyama, K.; Yamano, Y.; Sano, T.; Nakagomi, Y.; Hamakubo, T.; Morishima, I.; Inagami, T. Disulfide bridges in extracellular domains of angiotensin II receptor type IA. *Regul. Pept.* **1995**, *57*, 141–147. [[CrossRef](#)] [[PubMed](#)]
33. Wingler, L.M.; Skiba, M.A.; McMahon, C.; Staus, D.P.; Kleinhenz, A.L.W.; Suomivuori, C.-M.; Latorraca, N.R.; Dror, R.O.; Lefkowitz, R.J.; Kruse, A.C. Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR. *Science* **2020**, *367*, 888–892. [[CrossRef](#)] [[PubMed](#)]
34. Suomivuori, C.-M.; Latorraca, N.R.; Wingler, L.M.; Eismann, S.; King, M.C.; Kleinhenz, A.L.W.; Skiba, M.A.; Staus, D.P.; Kruse, A.C.; Lefkowitz, R.J.; et al. Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor. *Science* **2020**, *367*, 881–887. [[CrossRef](#)]
35. Aplin, M.; Bonde, M.M.; Hansen, J.L. Molecular determinants of angiotensin II type 1 receptor functional selectivity. *J. Mol. Cell. Cardiol.* **2009**, *46*, 15–24. [[CrossRef](#)] [[PubMed](#)]
36. Balakumar, P.; Jagadeesh, G. Structural determinants for binding, activation, and functional selectivity of the angiotensin AT1 receptor. *J. Mol. Endocrinol.* **2014**, *53*, R71–R92. [[CrossRef](#)]
37. Kaschina, E.; Unger, T. Angiotensin AT1/AT2 Receptors: Regulation, Signalling and Function. *Blood Press.* **2003**, *12*, 70–88. [[CrossRef](#)]

38. Freeman, E.J.; Chisolm, G.M.; Tallant, E.A. Role of calcium and protein kinase C in the activation of phospholipase D by angiotensin II in vascular smooth muscle cells. *Arch. Biochem. Biophys.* **1995**, *319*, 84–92. [[CrossRef](#)]
39. Lassegue, B.; Alexander, R.W.; Clark, M.; Akers, M.; Griendling, K.K. Phosphatidylcholine is a major source of phosphatidic acid and diacylglycerol in angiotensin II-stimulated vascular smooth-muscle cells. *Biochem. J.* **1993**, *292*, 509–517. [[CrossRef](#)]
40. Vinturache, A.E.; Smith, F.G. Angiotensin type 1 and type 2 receptors during ontogeny: Cardiovascular and renal effects. *Vasc. Pharmacol.* **2014**, *63*, 145–154. [[CrossRef](#)]
41. Rao, G.N.; Lassegue, B.; Alexander, R.W.; Griendling, K.K. Angiotensin II stimulates phosphorylation of high-molecular-mass cytosolic phospholipase A2 in vascular smooth-muscle cells. *Biochem. J.* **1994**, *299*, 197–201. [[CrossRef](#)]
42. Touyz, R.M.; Schiffrin, E.L. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. *Pharmacol. Rev.* **2000**, *52*, 639–672. [[PubMed](#)]
43. Ohtsu, H.; Suzuki, H.; Nakashima, H.; Dhobale, S.; Frank, G.D.; Motley, E.D.; Eguchi, S. Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells. *Hypertension* **2006**, *48*, 534–540. [[CrossRef](#)] [[PubMed](#)]
44. Kawai, T.; Forrester, S.J.; O'Brien, S.; Baggett, A.; Rizzo, V.; Eguchi, S. AT1 receptor signaling pathways in the cardiovascular system. *Pharmacol. Res.* **2017**, *125*, 4–13. [[CrossRef](#)] [[PubMed](#)]
45. Violin, J.D.; Lefkowitz, R.J. β -Arrestin-biased ligands at seven-transmembrane receptors. *Trends Pharmacol. Sci.* **2007**, *28*, 416–422. [[CrossRef](#)]
46. Luttrell, L.M.; Lefkowitz, R.J. The role of β -arrestins in the termination and transduction of G-protein-coupled receptor signals. *J. Cell Sci.* **2002**, *115*, 455–465. [[CrossRef](#)]
47. Tohgo, A.; Pierce, K.L.; Choy, E.W.; Lefkowitz, R.J.; Luttrell, L.M. β -Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation. *J. Biol. Chem.* **2002**, *277*, 9429–9436. [[CrossRef](#)]
48. Peterson, Y.K.; Luttrell, L.M. The Diverse Roles of Arrestin Scaffolds in G Protein–Coupled Receptor Signaling. *Pharmacol. Rev.* **2017**, *69*, 256–297. [[CrossRef](#)]
49. Griendling, K.K.; Minieri, C.A.; Ollerenshaw, J.D.; Alexander, R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ. Res.* **1994**, *74*, 1141–1148. [[CrossRef](#)]
50. Touyz, R.M.; Briones, A.M. Reactive oxygen species and vascular biology: Implications in human hypertension. *Hypertens. Res.* **2011**, *34*, 5–14. [[CrossRef](#)]
51. Tsutsumi, K.; Saavedra, J.M. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. *Am. J. Physiol.* **1991**, *261*, R209–R216. [[CrossRef](#)] [[PubMed](#)]
52. Ichiki, T.; Herold, C.L.; Kambayashi, Y.; Bardhan, S.; Inagami, T. Cloning of the cDNA and the genomic DNA of the mouse angiotensin II type 2 receptor. *Biochim. Biophys. Acta (BBA) Biomembr.* **1994**, *1189*, 247–250. [[CrossRef](#)]
53. Rompe, F.; Artuc, M.; Hallberg, A.; Alterman, M.; Ströder, K.; Thöne-Reineke, C.; Reichenbach, A.; Schacherl, J.; Dahlöf, B.; Bader, M.; et al. Direct Angiotensin II Type 2 Receptor Stimulation Acts Anti-Inflammatory Through Epoxyeicosatrienoic Acid and Inhibition of Nuclear Factor κ B. *Hypertension* **2010**, *55*, 924–931. [[CrossRef](#)]
54. Zhang, H.; Han, G.W.; Batyuk, A.; Ishchenko, A.; White, K.L.; Patel, N.; Sadybekov, A.; Zamlynyy, B.; Rudd, M.T.; Hollenstein, K.; et al. Structural basis for selectivity and diversity in angiotensin II receptors. *Nature* **2017**, *544*, 327–332. [[CrossRef](#)]
55. Griendling, K.K.; Lassegue, B.; Alexander, R.W. Angiotensin receptors and their therapeutic implications. *Annu. Rev. Pharmacol. Toxicol.* **1996**, *36*, 281–306. [[CrossRef](#)] [[PubMed](#)]
56. Zhang, J.; Pratt, R.E. The AT2 Receptor Selectively Associates with $G_{i\alpha 2}$ and $G_{i\alpha 3}$ in the Rat Fetus. *J. Biol. Chem.* **1996**, *271*, 15026–15033. [[CrossRef](#)]
57. Feng, Y.-H.; Saad, Y.; Karnik, S.S. Reversible inactivation of AT₂ angiotensin II receptor from cysteine–disulfide bond exchange. *FEBS Lett.* **2000**, *484*, 133–138. [[CrossRef](#)]
58. Heerding, J.N.; Yee, D.K.; Jacobs, S.L.; Fluharty, S.J. Mutational analysis of the angiotensin II type 2 receptor: Contribution of conserved extracellular amino acids. *Regul. Pept.* **1997**, *72*, 97–103. [[CrossRef](#)]
59. Yee, D.K.; Kisley, L.R.; Heerding, J.N.; Fluharty, S.J. Mutation of a conserved fifth transmembrane domain lysine residue (Lys²¹⁵) attenuates ligand binding in the angiotensin II type 2 receptor. *Brain Res. Mol. Brain Res.* **1997**, *51*, 238–241. [[CrossRef](#)]
60. Turner, C.A.; Cooper, S.; Pulakat, L. Role of the His273 located in the sixth transmembrane domain of the Angiotensin II receptor subtype AT2 in ligand–receptor interaction. *Biochem. Biophys. Res. Commun.* **1999**, *257*, 704–707. [[CrossRef](#)]
61. Steckelings, U.M.; Kaschina, E.; Unger, T. The AT2 receptor—A matter of love and hate. *Peptides* **2005**, *26*, 1401–1409. [[CrossRef](#)]
62. Turu, G.; Szidonya, L.; Gáborik, Z.; Buday, L.; Spät, A.; Clark, A.J.L.; Hunyady, L. Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors. *FEBS Lett.* **2006**, *580*, 41–45. [[CrossRef](#)] [[PubMed](#)]
63. Padia, S.H.; Carey, R.M. AT2 receptors: Beneficial counter-regulatory role in cardiovascular and renal function. *Pflug. Arch. Eur. J. Physiol.* **2013**, *465*, 99–110. [[CrossRef](#)] [[PubMed](#)]
64. Bottari, S.P.; Taylor, V.; King, I.N.; Bogdal, Y.; Whitebread, S.; de Gasparo, M. Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins. *Eur. J. Pharmacol. Mol. Pharmacol.* **1991**, *207*, 157–163. [[CrossRef](#)]
65. Stennett, A.K.; Qiao, X.; Falone, A.E.; Koledova, V.V.; Khalil, R.A. Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats. *Am. J. Physiol. Heart Circ. Physiol.* **2009**, *296*, H745–H755. [[CrossRef](#)] [[PubMed](#)]

66. Alexander, L.D.; Ding, Y.; Alagarsamy, S.; Cui, X. Angiotensin II stimulates fibronectin protein synthesis via a G $\beta\gamma$ /arachidonic acid-dependent pathway. *Am. J. Physiol. Ren. Physiol.* **2014**, *307*, F287–F302. [[CrossRef](#)]
67. Savoia, C.; Tabet, F.; Yao, G.; Schiffrin, E.L.; Touyz, R.M. Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: Role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. *J. Hypertens.* **2005**, *23*, 1037–1045. [[CrossRef](#)] [[PubMed](#)]
68. Savoia, C.; Ebrahimian, T.; He, Y.; Gratton, J.-P.; Schiffrin, E.L.; Touyz, R.M. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. *J. Hypertens.* **2006**, *24*, 2417–2422. [[CrossRef](#)] [[PubMed](#)]
69. Siragy, H.M.; Carey, R.M. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. *J. Clin. Investig.* **1997**, *100*, 264–269. [[CrossRef](#)]
70. Tsutsumi, Y.; Matsubara, H.; Masaki, H.; Kurihara, H.; Murasawa, S.; Takai, S.; Miyazaki, M.; Nozawa, Y.; Ozono, R.; Nakagawa, K.; et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. *J. Clin. Investig.* **1999**, *104*, 925–935. [[CrossRef](#)]
71. Yayama, K.; Hiyoshi, H.; Imazu, D.; Okamoto, H. Angiotensin II Stimulates Endothelial NO Synthase Phosphorylation in Thoracic Aorta of Mice With Abdominal Aortic Banding Via Type 2 Receptor. *Hypertension* **2006**, *48*, 958–964. [[CrossRef](#)] [[PubMed](#)]
72. Abadir, P.M.; Periasamy, A.; Carey, R.M.; Siragy, H.M. Angiotensin II Type 2 Receptor–Bradykinin B₂ Receptor Functional Heterodimerization. *Hypertension* **2006**, *48*, 316–322. [[CrossRef](#)] [[PubMed](#)]
73. Dimitropoulou, C.; White, R.E.; Fuchs, L.; Zhang, H.; Catravas, J.D.; Carrier, G.O. Angiotensin II Relaxes Microvessels Via the AT₂ Receptor and Ca²⁺-Activated K⁺ (BK_{Ca}) Channels. *Hypertension* **2001**, *37*, 301–307. [[CrossRef](#)] [[PubMed](#)]
74. Saavedra, J.M.; Armando, I. Angiotensin II AT₂ Receptors Contribute to Regulate the Sympathoadrenal and Hormonal Reaction to Stress Stimuli. *Cell. Mol. Neurobiol.* **2018**, *38*, 85–108. [[CrossRef](#)] [[PubMed](#)]
75. Foulquier, S.; Steckelings, U.M.; Unger, T. Perspective: A tale of two receptors. *Nature* **2013**, *493*, S9. [[CrossRef](#)]
76. Anderson, W.P.; Selig, S.E.; Korner, P.I. Role of Angiotensin II in the Hypertension Induced by Renal Artery Stenosis. *Clin. Exp. Hypertens. Part A Theory Pract.* **1984**, *6*, 299–314. [[CrossRef](#)]
77. Foulquier, S.; Steckelings, U.M.; Unger, T. Impact of the AT₂ Receptor Agonist C21 on Blood Pressure and Beyond. *Curr. Hypertens. Rep.* **2012**, *14*, 403–409. [[CrossRef](#)]
78. Fischer-Ferraro, C.; Nahmod, V.E.; Goldstein, D.J.; Finkelman, S. Angiotensin and renin in rat and dog brain. *J. Exp. Med.* **1971**, *133*, 353–361. [[CrossRef](#)]
79. Barnes, J.M.; Steward, L.J.; Barber, P.C.; Barnes, N.M. Identification and characterisation of angiotensin II receptor subtypes in human brain. *Eur. J. Pharmacol.* **1993**, *230*, 251–258. [[CrossRef](#)]
80. Vincent, J.-M.; Kwan, Y.W.; Lung Chan, S.; Perrin-Sarrado, C.; Atkinson, J.; Chillon, J.-M. Constrictor and Dilator Effects of Angiotensin II on Cerebral Arterioles. *Stroke* **2005**, *36*, 2691–2695. [[CrossRef](#)]
81. Dupuis, F.; Atkinson, J.; Limiñana, P.; Chillon, J.-M. Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. *J. Hypertens.* **2005**, *23*, 1061–1066. [[CrossRef](#)]
82. Foulquier, S.; Dupuis, F.; Perrin-Sarrado, C.; Maguin Gatè, K.; Leroy, P.; Liminana, P.; Atkinson, J.; Capdeville-Atkinson, C.; Lartaud, I. Differential Effects of Short-Term Treatment with Two AT₁ Receptor Blockers on Diameter of Pial Arterioles in SHR. *PLoS ONE* **2012**, *7*, e42469. [[CrossRef](#)]
83. Stenman, E.; Edvinsson, L. Cerebral Ischemia Enhances Vascular Angiotensin AT₁ Receptor–Mediated Contraction in Rats. *Stroke* **2004**, *35*, 970–974. [[CrossRef](#)]
84. Vikman, P.; Edvinsson, L. Gene expression profiling in the human middle cerebral artery after cerebral ischemia. *Eur. J. Neurol.* **2006**, *13*, 1324–1332. [[CrossRef](#)] [[PubMed](#)]
85. Chen, D.; Jancovski, N.; Bassi, J.K.; Nguyen-Huu, T.-P.; Choong, Y.-T.; Palma-Rigo, K.; Davern, P.J.; Gurley, S.B.; Thomas, W.G.; Head, G.A.; et al. Angiotensin Type 1A Receptors in C1 Neurons of the Rostral Ventrolateral Medulla Modulate the Pressor Response to Aversive Stress. *J. Neurosci.* **2012**, *32*, 2051–2061. [[CrossRef](#)] [[PubMed](#)]
86. De Kloet, A.D.; Wang, L.; Ludin, J.A.; Smith, J.A.; Pioquinto, D.J.; Hiller, H.; Steckelings, U.M.; Scheuer, D.A.; Summers, C.; Krause, E.G. Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system. *Brain Struct. Funct.* **2016**, *221*, 891–912. [[CrossRef](#)] [[PubMed](#)]
87. Gonzalez, A.D.; Wang, G.; Waters, E.M.; Gonzales, K.L.; Speth, R.C.; Van Kempen, T.A.; Marques-Lopes, J.; Young, C.N.; Butler, S.D.; Davisson, R.L.; et al. Distribution of angiotensin type 1a receptor-containing cells in the brains of bacterial artificial chromosome transgenic mice. *Neuroscience* **2012**, *226*, 489–509. [[CrossRef](#)] [[PubMed](#)]
88. Elsaafien, K.; de Kloet, A.D.; Krause, E.G.; Summers, C. Brain Angiotensin Type-1 and Type-2 Receptors in Physiological and Hypertensive Conditions: Focus on Neuroinflammation. *Curr. Hypertens. Rep.* **2020**, *22*, 48. [[CrossRef](#)] [[PubMed](#)]
89. De Kloet, A.D.; Wang, L.; Pitra, S.; Hiller, H.; Smith, J.A.; Tan, Y.; Nguyen, D.; Cahill, K.M.; Summers, C.; Stern, J.E.; et al. A Unique “Angiotensin-Sensitive” Neuronal Population Coordinates Neuroendocrine, Cardiovascular, and Behavioral Responses to Stress. *J. Neurosci.* **2017**, *37*, 3478–3490. [[CrossRef](#)]
90. De Kloet, A.D.; Pitra, S.; Wang, L.; Hiller, H.; Pioquinto, D.J.; Smith, J.A.; Summers, C.; Stern, J.E.; Krause, E.G. Angiotensin Type-2 Receptors Influence the Activity of Vasopressin Neurons in the Paraventricular Nucleus of the Hypothalamus in Male Mice. *Endocrinology* **2016**, *157*, 3167–3180. [[CrossRef](#)]

91. de Oliveira-Sales, E.B.; Nishi, E.E.; Boim, M.A.; Dolnikoff, M.S.; Bergamaschi, C.T.; Campos, R.R. Upregulation of AT1R and iNOS in the Rostral Ventrolateral Medulla (RVLM) Is Essential for the Sympathetic Hyperactivity and Hypertension in the 2K-1C Wistar Rat Model. *Am. J. Hypertens.* **2010**, *23*, 708–715. [[CrossRef](#)]
92. Li, Z.; Iwai, M.; Wu, L.; Shiuchi, T.; Jinno, T.; Cui, T.-X.; Horiuchi, M. Role of AT₂ receptor in the brain in regulation of blood pressure and water intake. *Am. J. Physiol. Heart Circ. Physiol.* **2003**, *284*, H116–H121. [[CrossRef](#)] [[PubMed](#)]
93. Gao, L.; Wang, W.-Z.; Wang, W.; Zucker, I.H. Imbalance of Angiotensin Type 1 Receptor and Angiotensin II Type 2 Receptor in the Rostral Ventrolateral Medulla: Potential Mechanism for Sympathetic Overactivity in Heart Failure. *Hypertension* **2008**, *52*, 708–714. [[CrossRef](#)] [[PubMed](#)]
94. Valero-Esquitino, V.; Lucht, K.; Namsolleck, P.; Monnet-Tschudi, F.; Stubbe, T.; Lucht, F.; Liu, M.; Ebner, F.; Brandt, C.; Danyel, L.A.; et al. Direct angiotensin type 2 receptor (AT₂R) stimulation attenuates T-cell and microglia activation and prevents demyelination in experimental autoimmune encephalomyelitis in mice. *Clin. Sci.* **2015**, *128*, 95–109. [[CrossRef](#)]
95. Kim, J.-H.; Afridi, R.; Cho, E.; Yoon, J.H.; Lim, Y.-H.; Lee, H.-W.; Ryu, H.; Suk, K. Soluble ANPEP Released From Human Astrocytes as a Positive Regulator of Microglial Activation and Neuroinflammation: Brain Renin–Angiotensin System in Astrocyte–Microglia Crosstalk. *Mol. Cell. Proteom.* **2022**, *21*, 100424. [[CrossRef](#)] [[PubMed](#)]
96. Rodriguez-Perez, A.I.; Borrajo, A.; Rodriguez-Pallares, J.; Guerra, M.J.; Labandeira-Garcia, J.L. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation: NADPH-Oxidase and Rho-Kinase Interaction. *Glia* **2015**, *63*, 466–482. [[CrossRef](#)]
97. Villar-Cheda, B.; Valenzuela, R.; Rodriguez-Perez, A.I.; Guerra, M.J.; Labandeira-Garcia, J.L. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration. *Neurobiol. Aging* **2012**, *33*, 204.e1–204.e11. [[CrossRef](#)]
98. Labandeira-Garcia, J.L.; Rodríguez-Perez, A.I.; Garrido-Gil, P.; Rodríguez-Pallares, J.; Lanciego, J.L.; Guerra, M.J. Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. *Front. Aging Neurosci.* **2017**, *9*, 129. [[CrossRef](#)]
99. Campbell, G.J.; Hands, E.L.; Van de Pette, M. The Role of CDKs and CDKIs in Murine Development. *Int. J. Mol. Sci.* **2020**, *21*, 5343. [[CrossRef](#)]
100. Han, H.J.; Han, J.Y.; Heo, J.S.; Lee, S.H.; Lee, M.Y.; Kim, Y.H. ANG II-stimulated DNA synthesis is mediated by ANG II receptor-dependent Ca²⁺/PKC as well as EGF receptor-dependent PI3K/Akt/mTOR/p70S6K1 signal pathways in mouse embryonic stem cells. *J. Cell. Physiol.* **2007**, *211*, 618–629. [[CrossRef](#)]
101. Diep, Q.N.; El Mabrouk, M.; Touyz, R.M.; Schiffrin, E.L. Expression of Cell Cycle Proteins in Blood Vessels of Angiotensin II-Infused Rats: Role of AT₁ Receptors. *Hypertension* **2001**, *37*, 604–608. [[CrossRef](#)]
102. Gingras, B.; Rodier, G.; Giasson, E.; Coulombe, P.; Chassagne, C.; Meloche, S. Expression of angiotensin type II receptor downregulates Cdk4 synthesis and inhibits cell-cycle progression. *Oncogene* **2003**, *22*, 2633–2642. [[CrossRef](#)] [[PubMed](#)]
103. Peluso, A.A.; Kempf, S.J.; Verano-Braga, T.; Rodrigues-Ribeiro, L.; Johansen, L.E.; Hansen, M.R.; Kitlen, G.; Haugaard, A.H.; Summers, C.; Ditzel, H.J.; et al. Quantitative Phosphoproteomics of the Angiotensin AT₂-Receptor Signaling Network Identifies HDAC1 (Histone-Deacetylase-1) and p53 as Mediators of Antiproliferation and Apoptosis. *Hypertension* **2022**, *79*, 2530–2541. [[CrossRef](#)] [[PubMed](#)]
104. Cubillos-Rojas, M.; Schneider, T.; Bartrons, R.; Ventura, F.; Rosa, J.L. NEURL4 regulates the transcriptional activity of tumor suppressor protein p53 by modulating its oligomerization. *Oncotarget* **2017**, *8*, 61824–61836. [[CrossRef](#)]
105. Yu, L.; Meng, W.; Ding, J.; Cheng, M. Klotho inhibits angiotensin II-induced cardiomyocyte hypertrophy through suppression of the AT1R/beta catenin pathway. *Biochem. Biophys. Res. Commun.* **2016**, *473*, 455–461. [[CrossRef](#)]
106. Zhou, L.; Liu, Y. Wnt/ β -catenin signaling and renin-angiotensin system in chronic kidney disease. *Curr. Opin. Nephrol. Hypertens.* **2016**, *25*, 100–106. [[CrossRef](#)] [[PubMed](#)]
107. Geisterfer, A.A.; Peach, M.J.; Owens, G.K. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. *Circ. Res.* **1988**, *62*, 749–756. [[CrossRef](#)]
108. Naftilan, A.J.; Pratt, R.E.; Dzau, V.J. Induction of Platelet-derived Growth Factor A-chain and c-myc Gene Expressions by Angiotensin II in Cultured Rat Vascular Smooth Muscle Cells. *J. Clin. Investig.* **1989**, *83*, 1419–1424. [[CrossRef](#)]
109. Wolf, G.; Wenzel, U.O. Angiotensin II and Cell Cycle Regulation. *Hypertension* **2004**, *43*, 693–698. [[CrossRef](#)]
110. Fujihara, S.; Morishita, A.; Ogawa, K.; Tadokoro, T.; Chiyo, T.; Kato, K.; Kobara, H.; Mori, H.; Iwama, H.; Masaki, T. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPK α /mTOR pathway in vitro and in vivo. *Oncotarget* **2017**, *8*, 8536–8549. [[CrossRef](#)]
111. Samukawa, E.; Fujihara, S.; Oura, K.; Iwama, H.; Yamana, Y.; Tadokoro, T.; Chiyo, T.; Kobayashi, K.; Morishita, A.; Nakahara, M.; et al. Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest. *Int. J. Oncol.* **2017**, *51*, 1674–1684. [[CrossRef](#)] [[PubMed](#)]
112. Du, H.; Liang, Z.; Zhang, Y.; Jie, F.; Li, J.; Fei, Y.; Huang, Z.; Pei, N.; Wang, S.; Li, A.; et al. Effects of Angiotensin II Type 2 Receptor Overexpression on the Growth of Hepatocellular Carcinoma Cells In Vitro and In Vivo. *PLoS ONE* **2013**, *8*, e83754. [[CrossRef](#)] [[PubMed](#)]
113. Arrieta, O.; Pineda-Olvera, B.; Guevara-Salazar, P.; Hernández-Pedro, N.; Morales-Espinosa, D.; Cerón-Lizarraga, T.L.; González-De la Rosa, C.H.; Rembao, D.; Segura-Pacheco, B.; Sotelo, J. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. *Br. J. Cancer* **2008**, *99*, 160–166. [[CrossRef](#)] [[PubMed](#)]

114. Dolley-Hitze, T.; Jouan, F.; Martin, B.; Mottier, S.; Edeline, J.; Moranne, O.; Le Pogamp, P.; Belaud-Rotureau, M.-A.; Patard, J.-J.; Rioux-Leclercq, N.; et al. Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? *Br. J. Cancer* **2010**, *103*, 1698–1705. [[CrossRef](#)]
115. Perini, M.V.; Dmello, R.S.; Nero, T.L.; Chand, A.L. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. *Pharmacol. Ther.* **2020**, *211*, 107527. [[CrossRef](#)]
116. Suganuma, T.; Ino, K.; Shibata, K.; Kajiyama, H.; Nagasaka, T.; Mizutani, S.; Kikkawa, F. Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination. *Clin. Cancer Res.* **2005**, *11*, 2686–2694. [[CrossRef](#)]
117. Rhodes, D.R.; Ateeq, B.; Cao, Q.; Tomlins, S.A.; Mehra, R.; Laxman, B.; Kalyana-Sundaram, S.; Lonigro, R.J.; Helgeson, B.E.; Bhojani, M.S.; et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 10284–10289. [[CrossRef](#)]
118. Tamura, M.; Yan, H.; Zegarra-Moro, O.; Edl, J.; Oursler, S.; Chard-Bergstrom, C.; Andrews, G.; Kanehira, T.; Takekoshi, S.; Mernaugh, R. Specific single chain variable fragment (ScFv) antibodies to angiotensin II AT2 receptor: Evaluation of the angiotensin II receptor expression in normal and tumor-bearing mouse lung. *J. Mol. Hist.* **2008**, *39*, 351–358. [[CrossRef](#)]
119. Pickel, L.; Matsuzuka, T.; Doi, C.; Ayuzawa, R.; Maurya, D.K.; Xie, S.-X.; Berkland, C.; Tamura, M. Over-expression of angiotensin II type 2 receptor gene induces cell death in lung adenocarcinoma cells. *Cancer Biol. Ther.* **2010**, *9*, 277–285. [[CrossRef](#)]
120. Pei, N.; Mao, Y.; Wan, P.; Chen, X.; Li, A.; Chen, H.; Li, J.; Wan, R.; Zhang, Y.; Du, H.; et al. Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer. *J. Exp. Clin. Cancer Res.* **2017**, *36*, 77. [[CrossRef](#)]
121. Ito, Y.; Naiki-Ito, A.; Kato, H.; Suzuki, S.; Kuno, T.; Ishiguro, Y.; Takahashi, S.; Uemura, H. Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor. *Oncotarget* **2018**, *9*, 13859–13869. [[CrossRef](#)] [[PubMed](#)]
122. Zhao, Y.; Lützen, U.; Fritsch, J.; Zuhayra, M.; Schütze, S.; Steckelings, U.M.; Recanti, C.; Namsoleck, P.; Unger, T.; Culman, J. Activation of intracellular angiotensin AT₂ receptors induces rapid cell death in human uterine leiomyosarcoma cells. *Clin. Sci.* **2015**, *128*, 567–578. [[CrossRef](#)] [[PubMed](#)]
123. Aleksiejczuk, M.; Gromotowicz-Poplawska, A.; Marcinczyk, N.; Przyłipiak, A.; Chabielska, E. The expression of the renin-angiotensin-aldosterone system in the skin and its effects on skin physiology and pathophysiology. *J. Physiol. Pharmacol.* **2019**, *70*. [[CrossRef](#)]
124. Silva, I.M.S.; Assersen, K.B.; Willadsen, N.N.; Jepsen, J.; Artuc, M.; Steckelings, U.M. The role of the renin-angiotensin system in skin physiology and pathophysiology. *Exp. Dermatol.* **2020**, *29*, 891–901. [[CrossRef](#)] [[PubMed](#)]
125. Viswanathan, M.; Saavedra, J.M. Expression of angiotensin II AT₂ receptors in the rat skin during experimental wound healing. *Peptides* **1992**, *13*, 783–786. [[CrossRef](#)] [[PubMed](#)]
126. Steckelings, U.M.; Henz, B.M.; Wiehstutz, S.; Unger, T.; Artuc, M. Differential expression of angiotensin receptors in human cutaneous wound healing. *Br. J. Dermatol.* **2005**, *153*, 887–893. [[CrossRef](#)]
127. Takeda, H.; Katagata, Y.; Kondo, S. Immunohistochemical study of angiotensin receptors in human anagen hair follicles and basal cell carcinoma. *Br. J. Dermatol.* **2002**, *147*, 276–280. [[CrossRef](#)]
128. Nehme, A.; Zouein, F.A.; Zayeri, Z.D.; Zibara, K. An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. *J. Cardiovasc. Dev. Dis.* **2019**, *6*, 14. [[CrossRef](#)]
129. Jiang, X.; Wu, F.; Xu, Y.; Yan, J.-X.; Wu, Y.-D.; Li, S.-H.; Liao, X.; Liang, J.-X.; Li, Z.-H.; Liu, H.-W. A novel role of angiotensin II in epidermal cell lineage determination: Angiotensin II promotes the differentiation of mesenchymal stem cells into keratinocytes through the p38 MAPK, JNK and JAK2 signalling pathways. *Exp. Dermatol.* **2019**, *28*, 59–65. [[CrossRef](#)]
130. Rha, E.Y.; Kim, J.W.; Kim, J.H.; Yoo, G. Angiotensin-Converting Enzyme Inhibitor, Captopril, Improves Scar Healing in Hypertensive Rats. *Int. J. Med. Sci.* **2021**, *18*, 975–983. [[CrossRef](#)]
131. Jadhav, S.S.; Sharma, N.; Meeks, C.J.; Mordwinkin, N.M.; Espinoza, T.B.; Roda, N.R.; DiZerega, G.S.; Hill, C.K.; Louie, S.G.; Rodgers, K.E. Effects of combined radiation and burn injury on the renin-angiotensin system: CRBI and renin-angiotensin system. *Wound Repair. Regen.* **2013**, *21*, 131–140. [[CrossRef](#)]
132. Kamińska, M.; Mogielnicki, A.; Stankiewicz, A.; Kramkowski, K.; Domaniewski, T.; Buczko, W.; Chabielska, E. Angiotensin II Via At1 Receptor Accelerates Arterial Thrombosis In Renovascular Hypertensive Rats. *J. Physiol. Pharmacol.* **2005**, *56*, 571–585. [[PubMed](#)]
133. Bernasconi, R.; Nyström, A. Balance and circumstance: The renin angiotensin system in wound healing and fibrosis. *Cell. Signal.* **2018**, *51*, 34–46. [[CrossRef](#)] [[PubMed](#)]
134. Yahata, Y.; Shirakata, Y.; Tokumaru, S.; Yang, L.; Dai, X.; Tohyama, M.; Tsuda, T.; Sayama, K.; Iwai, M.; Horiuchi, M.; et al. A Novel Function of Angiotensin II in Skin Wound Healing. *J. Biol. Chem.* **2006**, *281*, 13209–13216. [[CrossRef](#)] [[PubMed](#)]
135. Faghih, M.; Hosseini, S.M.; Smith, B.; Ansari, A.M.; Lay, F.; Ahmed, A.K.; Inagami, T.; Marti, G.P.; Harmon, J.W.; Walston, J.D.; et al. Knockout of Angiotensin AT₂ receptors accelerates healing but impairs quality. *Aging* **2015**, *7*, 1185–1197. [[CrossRef](#)]
136. Hedayatyanfard, K.; Haddadi, N.; Ziai, S.A.; Karim, H.; Niazi, F.; Steckelings, U.M.; Habibi, B.; Modarressi, A.; Dehpour, A. The renin-angiotensin system in cutaneous hypertrophic scar and keloid formation. *Exp. Dermatol.* **2020**, *29*, 902–909. [[CrossRef](#)] [[PubMed](#)]
137. Karppinen, S.-M.; Heljasvaara, R.; Gullberg, D.; Tasanen, K.; Pihlajaniemi, T. Toward understanding scarless skin wound healing and pathological scarring. *F1000Res* **2019**, *8*, 787. [[CrossRef](#)]

138. Murphy, A.M.; Wong, A.L.; Bezuhly, M. Modulation of angiotensin II signaling in the prevention of fibrosis. *Fibrogenes. Tissue Repair*. **2015**, *8*, 7. [[CrossRef](#)]
139. Murphy, A.; LeVatte, T.; Boudreau, C.; Midgen, C.; Gratzner, P.; Marshall, J.; Bezuhly, M. Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. *Plast. Reconstr. Surg.* **2019**, *144*, 803e–813e. [[CrossRef](#)]
140. Huang, Y.; Li, J.; Wang, Y.; Chen, D.; Huang, J.; Dai, W.; Peng, P.; Guo, L.; Lei, Y. Intradermal delivery of an angiotensin II receptor blocker using a personalized microneedle patch for treatment of hypertrophic scars. *Biomater. Sci.* **2023**, *11*, 583–595. [[CrossRef](#)]
141. Ito, M.; Oliverio, M.I.; Mannon, P.J.; Best, C.F.; Maeda, N.; Smithies, O.; Coffman, T.M. Regulation of blood pressure by the type 1A angiotensin II receptor gene. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 3521–3525. [[CrossRef](#)]
142. Siragy, H.M.; Inagami, T.; Ichiki, T.; Carey, R.M. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT₂) angiotensin receptor. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 6506–6510. [[CrossRef](#)] [[PubMed](#)]
143. Daviet, L.; Lehtonen, J.Y.; Tamura, K.; Griese, D.P.; Horiuchi, M.; Dzau, V.J. Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. *J. Biol. Chem.* **1999**, *274*, 17058–17062. [[CrossRef](#)] [[PubMed](#)]
144. Lopez-Illasaca, M.; Liu, X.; Tamura, K.; Dzau, V.J. The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. *Mol. Biol. Cell.* **2003**, *14*, 5038–5050. [[CrossRef](#)] [[PubMed](#)]
145. Mogi, M.; Iwai, M.; Horiuchi, M. Emerging Concepts of Regulation of Angiotensin II Receptors: New Players and Targets for Traditional Receptors. *Arterioscler. Thromb. Vasc. Biol.* **2007**, *27*, 2532–2539. [[CrossRef](#)]
146. Tanaka, Y.; Tamura, K.; Koide, Y.; Sakai, M.; Tsurumi, Y.; Noda, Y.; Umemura, M.; Ishigami, T.; Uchino, K.; Kimura, K.; et al. The novel angiotensin II type 1 receptor (AT1R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. *FEBS Lett.* **2005**, *579*, 1579–1586. [[CrossRef](#)]
147. Guo, D.-F.; Chenier, I.; Tardif, V.; Orlov, S.N.; Inagami, T. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. *Biochem. Biophys. Res. Commun.* **2003**, *310*, 1254–1265. [[CrossRef](#)]
148. Guo, D.-F.; Chenier, I.; Lavoie, J.L.; Chan, J.S.D.; Hamet, P.; Tremblay, J.; Chen, X.M.; Wang, D.H.; Inagami, T. Development of hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1 gene in the kidney. *Hypertension* **2006**, *48*, 453–459. [[CrossRef](#)]
149. Wruck, C.J.; Funke-Kaiser, H.; Pufe, T.; Kusserow, H.; Menk, M.; Sचेफे, J.H.; Kruse, M.L.; Stoll, M.; Unger, T. Regulation of transport of the angiotensin AT₂ receptor by a novel membrane-associated Golgi protein. *Arterioscl. Thromb. Vasc. Biol.* **2005**, *25*, 57–64. [[CrossRef](#)]
150. Reinemund, J.; Seidel, K.; Steckelings, U.M.; Zaade, D.; Klare, S.; Rompe, F.; Katerbaum, M.; Schacherl, J.; Li, Y.; Menk, M.; et al. Poly(ADP-ribose) polymerase-1 (PARP-1) transcriptionally regulates angiotensin AT₂ receptor (AT₂R) and AT₂R binding protein (ATBP) genes. *Biochem. Pharmacol.* **2009**, *77*, 1795–1805. [[CrossRef](#)]
151. Senbonmatsu, T.; Saito, T.; Landon, E.J.; Watanabe, O.; Price, E.J.; Roberts, R.L.; Imboden, H.; Fitzgerald, T.G.; Gaffney, F.A.; Inagami, T. A novel angiotensin II type 2 receptor signaling pathway: Possible role in cardiac hypertrophy. *EMBO J.* **2003**, *22*, 6471–6482. [[CrossRef](#)]
152. Foulquier, S.; Dupuis, F.; Perrin-Sarrado, C.; Maguin Gaté, K.; Merhi-Soussi, F.; Liminana, P.; Kwan, Y.-W.; Capdeville-Atkinson, C.; Lartaud, I.; Atkinson, J. High salt intake abolishes AT₂-mediated vasodilation of pial arterioles in rats. *J. Hypertens.* **2011**, *29*, 1392–1399. [[CrossRef](#)]
153. AbdAlla, S.; Lothar, H.; Langer, A.; el Faramawy, Y.; Quitterer, U. Factor XIIIa Transglutaminase Crosslinks AT₁ Receptor Dimers of Monocytes at the Onset of Atherosclerosis. *Cell* **2004**, *119*, 343–354. [[CrossRef](#)]
154. Oro, C.; Qian, H.; Thomas, W.G. Type 1 angiotensin receptor pharmacology: Signaling beyond G proteins. *Pharmacol. Ther.* **2007**, *113*, 210–226. [[CrossRef](#)]
155. AbdAlla, S.; Lothar, H.; Quitterer, U. AT₁-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature* **2000**, *407*, 94–98. [[CrossRef](#)]
156. Bokslag, A.; van Weissenbruch, M.; Mol, B.W.; de Groot, C.J.M. Preeclampsia; short and long-term consequences for mother and neonate. *Early Hum. Dev.* **2016**, *102*, 47–50. [[CrossRef](#)] [[PubMed](#)]
157. Quitterer, U.; AbdAlla, S. Pathological AT₁R-B₂R Protein Aggregation and Preeclampsia. *Cells* **2021**, *10*, 2609. [[CrossRef](#)] [[PubMed](#)]
158. Kostenis, E.; Milligan, G.; Christopoulos, A.; Sanchez-Ferrer, C.F.; Heringer-Walther, S.; Sexton, P.M.; Gembardt, F.; Kellett, E.; Martini, L.; Vanderheyden, P.; et al. G-Protein-Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor. *Circulation* **2005**, *111*, 1806–1813. [[CrossRef](#)]
159. Miura, S.; Karnik, S.S.; Saku, K. Constitutively Active Homo-oligomeric Angiotensin II Type 2 Receptor Induces Cell Signaling Independent of Receptor Conformation and Ligand Stimulation. *J. Biol. Chem.* **2005**, *280*, 18237–18244. [[CrossRef](#)] [[PubMed](#)]
160. Porrello, E.R.; Pfleger, K.D.G.; Seeber, R.M.; Qian, H.; Oro, C.; Abogadie, F.; Delbridge, L.M.D.; Thomas, W.G. Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. *Cell. Signal.* **2011**, *23*, 1767–1776. [[CrossRef](#)]
161. Zha, D.; Cheng, H.; Li, W.; Wu, Y.; Li, X.; Zhang, L.; Feng, Y.-H.; Wu, X. High glucose instigates tubulointerstitial injury by stimulating hetero-dimerization of adiponectin and angiotensin II receptors. *Biochem. Biophys. Res. Commun.* **2017**, *493*, 840–846. [[CrossRef](#)]

162. Abadir, P.M.; Carey, R.M.; Siragy, H.M. Angiotensin AT₂ Receptors Directly Stimulate Renal Nitric Oxide in Bradykinin B₂-Receptor–Null Mice. *Hypertension* **2003**, *42*, 600–604. [[CrossRef](#)]
163. Zhao, Y.; Biermann, T.; Luther, C.; Unger, T.; Culman, J.; Gohlke, P. Contribution of bradykinin and nitric oxide to AT₂ receptor-mediated differentiation in PC12 W cells: Angiotensin II and PC12 W cell differentiation. *J. Neurochem.* **2003**, *85*, 759–767. [[CrossRef](#)] [[PubMed](#)]
164. Patel, S.N.; Ali, Q.; Samuel, P.; Steckelings, U.M.; Hussain, T. Angiotensin II Type 2 Receptor and Receptor Mas Are Colocalized and Functionally Interdependent in Obese Zucker Rat Kidney. *Hypertension* **2017**, *70*, 831–838. [[CrossRef](#)] [[PubMed](#)]
165. Walters, P.E.; Gaspari, T.A.; Widdop, R.E. Angiotensin-(1–7) Acts as a Vasodepressor Agent Via Angiotensin II Type 2 Receptors in Conscious Rats. *Hypertension* **2005**, *45*, 960–966. [[CrossRef](#)]
166. Durand, M.J.; Raffai, G.; Weinberg, B.D.; Lombard, J.H. Angiotensin-(1–7) and low-dose angiotensin II infusion reverse salt-induced endothelial dysfunction via different mechanisms in rat middle cerebral arteries. *Am. J. Physiol. Heart Circ. Physiol.* **2010**, *299*, H1024–H1033. [[CrossRef](#)]
167. Roks, A.J.; Nijholt, J.; van Buiten, A.; van Gilst, W.H.; de Zeeuw, D.; Henning, R.H. Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1–7) on angiotensin II. *J. Hypertens.* **2004**, *22*, 2355–2361. [[CrossRef](#)]
168. Leonhardt, J.; Villela, D.C.; Teichmann, A.; Münter, L.-M.; Mayer, M.C.; Mardahl, M.; Kirsch, S.; Namsolleck, P.; Lucht, K.; Benz, V.; et al. Evidence for Heterodimerization and Functional Interaction of the Angiotensin Type 2 Receptor and the Receptor MAS. *Hypertension* **2017**, *69*, 1128–1135. [[CrossRef](#)]
169. Lemos, V.S.; Silva, D.M.R.; Walther, T.; Alenina, N.; Bader, M.; Santos, R.A.S. The Endothelium-Dependent Vasodilator Effect of the Nonpeptide Ang(1–7) Mimic AVE 0991 Is Abolished in the Aorta of Mas-Knockout Mice. *J. Cardiovasc. Pharmacol.* **2005**, *46*, 274–279. [[CrossRef](#)]
170. AbdAlla, S.; Lothar, H.; Abdel-tawab, A.M.; Quitterer, U. The Angiotensin II AT₂ Receptor Is an AT₁Receptor Antagonist. *J. Biol. Chem.* **2001**, *276*, 39721–39726. [[CrossRef](#)] [[PubMed](#)]
171. Inuzuka, T.; Fujioka, Y.; Tsuda, M.; Fujioka, M.; Satoh, A.O.; Horiuchi, K.; Nishide, S.; Nanbo, A.; Tanaka, S.; Ohba, Y. Attenuation of ligand-induced activation of angiotensin II type 1 receptor signaling by the type 2 receptor via protein kinase C. *Sci Rep* **2016**, *6*, 21613. [[CrossRef](#)] [[PubMed](#)]
172. Rivas-Santisteban, R.; Rodriguez-Perez, A.I.; Muñoz, A.; Reyes-Resina, I.; Labandeira-García, J.L.; Navarro, G.; Franco, R. Angiotensin AT₁ and AT₂ receptor heteromer expression in the hemilesioned rat model of Parkinson’s disease that increases with levodopa-induced dyskinesia. *J. Neuroinflamm.* **2020**, *17*, 243. [[CrossRef](#)] [[PubMed](#)]
173. Lanctôt, P.M.; Leclerc, P.C.; Escher, E.; Leduc, R.; Guillemette, G. Role of N-glycosylation in the expression and functional properties of human AT₁ receptor. *Biochemistry* **1999**, *38*, 8621–8627. [[CrossRef](#)]
174. Lanctot, P.M.; Leclerc, P.C.; Clément, M.; Auger-Messier, M.; Escher, E.; Leduc, R.; Guillemette, G. Importance of N-glycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT₁ receptor. *Biochem. J.* **2005**, *390*, 367–376. [[CrossRef](#)] [[PubMed](#)]
175. Servant, G.; Dudley, D.T.; Escher, E.; Guillemette, G. The marked disparity between the sizes of angiotensin type 2 receptors from different tissues is related to different degrees of N-glycosylation. *Mol. Pharmacol.* **1994**, *45*, 1112–1118.
176. Servant, G.; Dudley, D.T.; Escher, E.; Guillemette, G. Analysis of the role of N-glycosylation in cell-surface expression and binding properties of angiotensin II type-2 receptor of rat pheochromocytoma cells. *Biochem. J.* **1996**, *313*, 297–304. [[CrossRef](#)] [[PubMed](#)]
177. Qian, H. Association of -Arrestin 1 with the Type 1A Angiotensin II Receptor Involves Phosphorylation of the Receptor Carboxyl Terminus and Correlates with Receptor Internalization. *Mol. Endocrinol.* **2001**, *15*, 1706–1719. [[CrossRef](#)]
178. Kule, C.E.; Karoor, V.; Day, J.N.E.; Thomas, W.G.; Baker, K.M.; Dinh, D.; Acker, K.A.; Booz, G.W. Agonist-dependent internalization of the angiotensin II type one receptor (AT₁): Role of C-terminus phosphorylation in recruitment of β-arrestins. *Regul. Pept.* **2004**, *120*, 141–148. [[CrossRef](#)]
179. Chen, K.; Fu, C.; Chen, C.; Jose, P.A.; Zeng, C. Role of GRK4 in the Regulation of Arterial AT₁ Receptor in Hypertension. *J. Am. Soc. Hypertens.* **2016**, *10*, e3. [[CrossRef](#)]
180. Olivares-Reyes, J.A.; Smith, R.D.; Hunyady, L.; Shah, B.H.; Catt, K.J. Agonist-induced Signaling, Desensitization, and Internalization of a Phosphorylation-deficient AT_{1A} Angiotensin Receptor. *J. Biol. Chem.* **2001**, *276*, 37761–37768. [[CrossRef](#)]
181. Zhang, F.; Lei, L.; Huang, J.; Wang, W.; Su, Q.; Yan, H.; Chen, C.; Zheng, S.; Ren, H.; Li, Z.; et al. G-protein-coupled receptor kinase 4 causes renal angiotensin II type 2 receptor dysfunction by increasing its phosphorylation. *Clin. Sci.* **2022**, *136*, 989–1003. [[CrossRef](#)] [[PubMed](#)]
182. Leclerc, P.C.; Lanctot, P.M.; Auger-Messier, M.; Escher, E.; Leduc, R.; Guillemette, G. S-nitrosylation of cysteine 289 of the AT₁ receptor decreases its binding affinity for angiotensin II: S -nitrosylation of the AT₁ receptor. *Br. J. Pharmacol.* **2006**, *148*, 306–313. [[CrossRef](#)] [[PubMed](#)]
183. Jang, J.H.; Chun, J.N.; Godo, S.; Wu, G.; Shimokawa, H.; Jin, C.Z.; Jeon, J.H.; Kim, S.J.; Jin, Z.H.; Zhang, Y.H. ROS and endothelial nitric oxide synthase (eNOS)-dependent trafficking of angiotensin II type 2 receptor begets neuronal NOS in cardiac myocytes. *Basic Res. Cardiol.* **2015**, *110*, 21. [[CrossRef](#)]
184. Sica, D.A.; Gehr, T.W.B.; Ghosh, S. Clinical Pharmacokinetics of Losartan. *Clin. Pharmacokinet.* **2005**, *44*, 797–814. [[CrossRef](#)]
185. Barber, M.N.; Sampey, D.B.; Widdop, R.E. AT₂ Receptor Stimulation Enhances Antihypertensive Effect of AT₁ Receptor Antagonist in Hypertensive Rats. *Hypertension* **1999**, *34*, 1112–1116. [[CrossRef](#)]

186. Ewert, S.; Laesser, M.; Johansson, B.; Holm, M.; Aneman, A.; Fandriks, L. The angiotensin II receptor type 2 agonist CGP 42112A stimulates NO production in the porcine jejunal mucosa. *BMC Pharmacol.* **2003**, *3*, 2. [[CrossRef](#)] [[PubMed](#)]
187. Wan, Y.; Wallinder, C.; Plouffe, B.; Beaudry, H.; Mahalingam, A.K.; Wu, X.; Johansson, B.; Holm, M.; Botoros, M.; Karlén, A.; et al. Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT₂ Receptor Agonist. *J. Med. Chem.* **2004**, *47*, 5995–6008. [[CrossRef](#)]
188. Carey, R. Role of the angiotensin AT₂ receptor in blood pressure regulation and therapeutic implications. *Am. J. Hypertens.* **2001**, *14*, S98–S102. [[CrossRef](#)]
189. Sumners, C.; de Kloet, A.D.; Krause, E.G.; Unger, T.; Steckelings, U.M. Angiotensin type 2 receptors: Blood pressure regulation and end organ damage. *Curr. Opin. Pharmacol.* **2015**, *21*, 115–121. [[CrossRef](#)]
190. Zizzo, M.G.; Caldara, G.; Bellanca, A.; Nuzzo, D.; Di Carlo, M.; Serio, R. PD123319, angiotensin II type II receptor antagonist, inhibits oxidative stress and inflammation in 2, 4-dinitrobenzene sulfonic acid-induced colitis in rat and ameliorates colonic contractility. *Inflammopharmacology* **2020**, *28*, 187–199. [[CrossRef](#)]
191. Wagenaar, G.T.M.; Sengers, R.M.A.; Laghmani, E.H.; Chen, X.; Lindeboom, M.P.H.A.; Roks, A.J.M.; Folkerts, G.; Walther, F.J. Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2014**, *307*, L261–L272. [[CrossRef](#)] [[PubMed](#)]
192. Dupuis, F.; Vincent, J.-M.; Limiñana, P.; Chillon, J.-M.; Capdeville-Atkinson, C.; Atkinson, J. Effects of suboptimal doses of the AT₁ receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat. *J. Hypertens.* **2010**, *28*, 1566–1573. [[CrossRef](#)] [[PubMed](#)]
193. Budzyn, K.; Sobey, C.G.; Drummond, G.R. Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: Is less really more? *J. Hypertens.* **2010**, *28*, 1384–1389. [[CrossRef](#)] [[PubMed](#)]
194. Bosnyak, S.; Jones, E.S.; Christopoulos, A.; Aguilar, M.-I.; Thomas, W.G.; Widdop, R.E. Relative affinity of angiotensin peptides and novel ligands at AT₁ and AT₂ receptors. *Clin. Sci.* **2011**, *121*, 297–303. [[CrossRef](#)]
195. Teixeira, L.B.; Parreiras-e-Silva, L.T.; Bruder-Nascimento, T.; Duarte, D.A.; Simões, S.C.; Costa, R.M.; Rodríguez, D.Y.; Ferreira, P.A.B.; Silva, C.A.A.; Abrao, E.P.; et al. Ang-(1-7) is an endogenous β -arrestin-biased agonist of the AT₁ receptor with protective action in cardiac hypertrophy. *Sci. Rep.* **2017**, *7*, 11903. [[CrossRef](#)]
196. Wei, H.; Ahn, S.; Shenoy, S.K.; Karnik, S.S.; Hunyady, L.; Luttrell, L.M.; Lefkowitz, R.J. Independent β -arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 10782–10787. [[CrossRef](#)]
197. Violin, J.D.; DeWire, S.M.; Yamashita, D.; Rominger, D.H.; Nguyen, L.; Schiller, K.; Whalen, E.J.; Gowen, M.; Lark, M.W. Selectively engaging β -arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. *J. Pharmacol. Exp. Ther.* **2010**, *335*, 572–579. [[CrossRef](#)] [[PubMed](#)]
198. Timmermans, P.B.; Carini, D.J.; Chiu, A.T.; Duncia, J.V.; Price, W.A.J.; Wells, G.J.; Wong, P.C.; Johnson, A.L.; Wexler, R.R. The discovery of a new class of highly specific nonpeptide angiotensin II receptor antagonists. *Am. J. Hypertens.* **1991**, *4*, 275S–281S. [[CrossRef](#)]
199. Vanderheyden, P.M.L.; Fierens, F.L.P.; De Backer, J.P.; Fraeyman, N.; Vauquelin, G. Distinction between surmountable and insurmountable selective AT₁ receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT₁ receptors: Insurmountable antagonism of candesartan. *Br. J. Pharmacol.* **1999**, *126*, 1057–1065. [[CrossRef](#)]
200. De Gasparo, M.; Whitebread, S. Binding of valsartan to mammalian angiotensin AT₁ receptors. *Regul. Pept.* **1995**, *59*, 303–311. [[CrossRef](#)]
201. McClellan, K.J.; Markham, A. Telmisartan. *Drugs* **1998**, *56*, 1039–1044; discussion 1045–1046. [[CrossRef](#)]
202. Dudley, D.T.; Summerfelt, R.M. Regulated expression of angiotensin II (AT₂) binding sites in R3T3 cells. *Regul. Pept.* **1993**, *44*, 199–206. [[CrossRef](#)] [[PubMed](#)]
203. Cui, Y.; Kassmann, M.; Nickel, S.; Zhang, C.; Alenina, N.; Anistan, Y.M.; Schleifenbaum, J.; Bader, M.; Welsh, D.G.; Huang, Y.; et al. Myogenic Vasoconstriction Requires Canonical G_{q/11} Signaling of the Angiotensin II Type 1 Receptor. *J. Am. Heart Assoc.* **2022**, *11*, e022070. [[CrossRef](#)]
204. Jean-Charles, P.-Y.; Kaur, S.; Shenoy, S.K. G Protein–Coupled Receptor Signaling Through β -Arrestin–Dependent Mechanisms. *J. Cardiovasc. Pharmacol.* **2017**, *70*, 142–158. [[CrossRef](#)] [[PubMed](#)]
205. Ma, Z.; Viswanathan, G.; Sellig, M.; Jassal, C.; Choi, I.; Garikipati, A.; Xiong, X.; Nazo, N.; Rajagopal, S. β -Arrestin–Mediated Angiotensin II Type 1 Receptor Activation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension. *JACC Basic Transl. Sci.* **2021**, *6*, 854–869. [[CrossRef](#)] [[PubMed](#)]
206. Boerrigter, G.; Soergel, D.G.; Lark, M.W.; Burnett, J.C. TRV120027, a Novel Beta-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure. *J. Card. Fail.* **2011**, *17*, S63–S64. [[CrossRef](#)]
207. Kanki, H.; Sasaki, T.; Matsumura, S.; Yokawa, S.; Yukami, T.; Shimamura, M.; Sakaguchi, M.; Furuno, T.; Suzuki, T.; Mochizuki, H. β -arrestin-2 in PAR-1-biased signaling has a crucial role in endothelial function via PDGF- β in stroke. *Cell Death Dis.* **2019**, *10*, 100. [[CrossRef](#)]

208. Bouressam, M.; Lecat, S.; Raoul, A.; Gaucher, C.; Perrin-Sarrado, C.; Lartaud, I.; Dupuis, F. S-nitrosoglutathione inhibits cerebrovascular angiotensin II-dependent and -independent AT₁ receptor responses: A possible role of S-nitrosation. *Br. J. Pharmacol.* **2019**, *176*, 2049–2062. [[CrossRef](#)]
209. Pinheiro, L.C.; Oliveira-Paula, G.H.; Ferreira, G.C.; Dal-Cin de Paula, T.; Duarte, D.A.; Costa-Neto, C.M.; Tanus-Santos, J.E. Oral nitrite treatment increases S-nitrosylation of vascular protein kinase C and attenuates the responses to angiotensin II. *Redox Biol.* **2021**, *38*, 101769. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.